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Chapter 1 
GENERAL INTRODUCTION 
Recurrent miscarriage is a problem affecting 0.5 - 1 % of couples in their reproductive 
years [Alberman, 1988; Regan, 1992]. Many possible etologie factors and treatment 
protocols have been proposed [Stirrat, 1990a; 1990b]. However, the pathophysiology 
of recurrent miscarriage is still poorly understood. 
A recent preliminary study has suggested a relationship between recurrent sponta-
neous abortion and hyperhomocysteinemia, i.e. a derangement of methionine-homo-
cysteine metabolism resulting in elevated blood concentrations of homocysteine 
[Steegers-Theunissen et al., 1992a]. The present thesis was designed to explore this 
possible association. 
The general objectives of this thesis are: 
1. to study the homocysteine status of women with recurrent miscarriage and 
with normal pregnancy outcome; 
2. to evaluate the role of possible determinants of hyperhomocysteinemia in 
women with recurrent miscarriage, in particular vitamins and enzymes invol-
ved in homocysteine metabolism; 
3. to examine the effects of vitamin administration on: 
a. elevated plasma homocysteine concentrations, and 
b. subsequent pregnancy outcome in women with recurrent miscarriage. 
Chapter 2 gives an overview of the etiology and management of recurrent miscarria-
ge. Chapter 3 reviews the biochemical, (patho)physiological and clinical aspects of 
hyperhomocysteinemia, with special attention to vascular disease and adverse 
pregnancy outcome. In chapter 4, the objectives, design and laboratory methods of 
this thesis are described. The results from the studies performed are presented in 
chapter 5 to 11. In chapter 12, the significance of the results is discussed and some 
suggestions for future research and clinical management are given. 
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Chapter 2 
RECURRENT MISCARRIAGE: AN OVERVIEW 
DEFINITION 
In the Netherlands, spontaneous abortion or miscarriage is defined as the expulsion 
of the conceptus within 16 weeks (112 days) from the onset of the last menses 
[Kloosterman, 1975]. The World Health Organization has defined spontaneous 
abortion as the expulsion or extraction of an embryo or fetus weighing 500 g or less 
(approximately equal to 20-22 weeks of gestation) [WHO, 1977]. By some investiga-
tors, spontaneous abortion is defined as pregnancy loss until 28 weeks of gestation. 
First trimester spontaneous abortion usually refers to pregnancy loss before 12-14 
weeks of gestation. 
Recurrent spontaneous abortion has traditionally been defined as three or more 
consecutive miscarriages with the same partner [Stirrat, 1990a]. Lately, a definition of 
two or more spontaneous abortions is more frequently used, because couples and 
doctors are prompted sooner to initiate investigation for potential causes. This 
tendency towards a less rigorous definition may be justified by the observation of an 
equal distribution of possible etiologic factors in couples with a history of two or more 
miscarriages and those with three or more [Coulam, 1991]. 
INCIDENCE 
The incidence of spontaneous abortion among clinically recognized pregnancies 
varies between 12 and 15% [Warburton and Fraser, 1964; Miller et al., 1980; 
Edmonds et al., 1982; Whittaker et al., 1983; Wilcox et al., 1988; Regan et al., 1989]. 
The measurement of human chorionic gonadotropin (hCG) in serum or urine is the 
most specific biochemical test for early pregnancy at or soon after the time of 
implantation. Due to the development of highly sensitive assays for hCG, it was 
demonstrated that the incidence of spontaneous abortion after implantation exceeds 
the number of clinically recognized early pregnancy losses, and probably is between 
20 and 60% [Miller et al., 1980; Edmonds et al., 1982; Whittaker et al., 1983; Wilcox 
et al., 1988]. The "true" incidence of spontaneous abortion, i.e. the rate of pregnancy 
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loss after conception, has been estimated as high as 70 - 80% [Roberts and Lowe, 
1975; Chard, 1991]. 
The incidence of recurrent miscarriage has never been reliably determined. Some 
investigators state that recurrent miscarriage merely results from chance [Vlaande-
ren, 1983; Huisjes, 1984]. Given the incidence of sporadic abortion (12 -15%), one 
may calculate that the probability of two and three consecutive miscarriages would be 
1.0 - 2.3% and 0.1 - 0.3%, respectively. It is estimated, however, that 0.5 - 1 % of the 
reproducing couples experience three or more consecutive spontaneous abortions, a 
proportion which is higher than the random risk [Alberman, 1988; Regan, 1992]. This 
data suggests that some women are more prone to having miscarriages, thus 
implicating there may be an underlying cause for these losses. 
ETIOLOGY 
Many potential causes have been proposed for recurrent miscarriage. Their etiologic 
significance has been extensively evaluated in recent reviews [Stirrat, 1990b; Regan, 
1992; Hill, 1994]. The only noncontroversial cause is a chromosomal abnormality, 
most commonly a balanced translocation in one or both partners. All other possible 
etiologic factors are presumed ones on the basis of their association with recurrent 
miscarriage. 
Case-(control) studies are most useful to assess the frequency of a potential cause 
among women with recurrent miscarriage (Table 2.1). The wide ranges of frequency 
that are reported may result from the use of different criteria for selecting populations, 
and different diagnostic techniques for measuring the same variable. The principal 
limitation of case-(control) studies results from the fact that data are obtained after 
the occurrence of disease. Therefore, it may be inconclusive whether a factor is 
causative, coincidental or a consequence of recurrent miscarriage. In this respect, 
prospective studies seem to be more appropiate. Their significance will be discussed 
in the next section. 
The proportion of women with unexplained recurrent spontaneous abortion, i.e. 
without evidence for any potential etiology, has been reported between 24 and 60% 
[Tho et al., 1979; Harger et al., 1983; Stray-Pedersen and Stray-Pedersen, 1984; 
Parazzini et al., 1988; Plouffe et al., 1992; Tulppala et al., 1993a]. 
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Table 2.1. Frequencies of potential etiologies in women with recurrent miscamage and controls 
Potential etiology Frequency * Referencesf 
Chromosomal abnormalities 
Balanced translocations 
Inversions 
Uterine malformations 
Müllenan duct anomalies 
Intrauterine adhesions 
Endocrine disorders 
Polycystic ovary syndrome 
Luteal phase defect 
Thyroid dysfunction 
Impaired glucose tolerance 
Autoimmunological disorders 
Lupus anticoagulant 
Anticardiolipin antibodies 
Antinuclear antibodies 
Antithyroid antibodies 
Alloimmunological disorders 
Parental sharing of HLAi 
Lymphocytotoxic antibodies 
Lack of blocking antibodies 
Reproductive tract infections 
Ureaplasma urealyticum 
Chlamydia trachomatis 
Nutritional deficiency 
Folate deficiency 
Recurrent miscarriage 
1 8 - 4 8 % 
0 2 - 0 6 % 
2-18% 
0-7% 
44 - 82% 
5-60% 
2 -9% 
0% 
0 - 1 1 % 
6-19% 
7 - 30% 
17-40% 
15-41% 
26-46% 
58 - 80% 
15-48% 
1-48% 
30 -41% 
Controls 
0 2% 
0 01% 
2% 
? 
10-23% 
5 - 50% 
? 
? 
0-4% 
0 - 4% 
0 - 20% 
6-19% 
63% 
63% 
56% 
? 
? 
6-22% 
9 16,28 
9.16,28 
1,3,11,17,22,27,29,31 
11,22,27,29,31 
3,23,25,32,33 
7,8,19,22,26,30 
22,27 
22,31 
2,10,14,15,16,18 
2,6,10,14,15,16,18 
5,12,20,31,35 
24,31 
4,6 
4,6 
4,6 
11,27 
22,34 
13,21 
* Given as ranges, f In alphabetical order 1 Ashton et al, 198В, 2 Balasch et al, 1990, 3 Clifford et 
al, 1994, 4 Coulam, 1992, 5 Cowchock et al, 19Θ6, 6 Cowchock and Smith, 1992, 7 Davis et al, 
19Θ9, 8 Dayaetal, 1988, 9 De Braekeleer & Nao, 1990, 10 Eroglu and Scopelitis, 1994, 11 Hanger 
et al, 1983, 12 Hargeretal, 1989, 13 Hibbard, 1964, 14 Infante-Rivard et al. 1991, 15 MacLeanet 
al, 1994, 16 Olson and Magenis, 1988, 17 Parazzim et al, 1988, 18 Parazzim et al, 1991, 19 
Peters et al, 1992, 20 Petnetal, 1987, 21 Pietznketal, 1992, 22 Plouffeetal, 1992, 23 Poison et 
al, 1988, 24 Pratt et al, 1993b, 25 Sagleetal, 1988, 26 Serte et al, 1994, 27 Stray-Pedersen and 
Stray-Pedersen, 1984, 28 Tharapel et al, 1985, 29 Tho et al, 1979, 30 Tulppala et al, 1991, 31 
Tulppala et al, 1993a,32 Tulppala et al, 1993b,33 Watson et al, 1993,34 Witkm and Ledger, 1992, 
35 Xu et al, 1990, t Human leukocyte antigen(s) 
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MANAGEMENT 
Couples with recurrent miscarriage seek medical help for their eagerness of having a 
healthy child in the next pregnancy. Management of these couples should be aimed 
at a) identifying those factors that predict subsequent pregnancy outcome (prognostic 
profile), and, if possible, b) improving their chances of achieving a normal pregnancy 
(treatment). 
Prognostic profile 
At present, routine investigation procedures are usually based on exploring all factors 
that are possibly etiologic to recurrent miscarriage. Instead, they should be limited to 
the evaluation of those factors that are likely to be significant to a couple's prognosis. 
In this respect, obstetric history including the number of previous miscarriages and 
successful pregnancies, and maternal age have been proposed as important 
prognostic variables (Table 2.2). Their true effects, however, are difficult to assess 
because 1) women with consecutive miscarriages may continue their attempt to 
achieve a successful pregnancy after other women have completed their family 
(reproductive compensation), and 2) a higher number of pregnancies is also associa-
ted with more advanced maternal age [Simpson, 1990; Stirrat, 1990a]. 
If a potential cause for recurrent miscarriage is truly etiologic, it should predict a 
significantly lower success rate for the next pregnancy. Prospective studies, in 
particular those without any therapeutic intervention, seem most appropiate to 
examine the prognostic significance of potential etiologies. Few such studies, 
however, have been conducted among women with recurrent miscarriage (Table 
2.3). Hypersecretion of luteinizing hormone (LH), hyperandrogenism, oligomenor-
rhea, and presence of anticardiolipin antibodies and antithyroid antibodies seem to 
result in significantly lower success rates after experiencing consecutive miscarria-
ges. The prognostic value of these factors, however, should be reconfirmed. As yet, 
the prognostic significance of chromosomal abnormalities has not been properly 
evaluated despite their general acceptance as a cause for recurrent miscarriage. 
Future studies should assess the relative importance of each factor in predicting 
success rates. In line with this view, Quenby and Farquharson (1993) have recently 
formulated a mathematical model that described their observational data on 203 
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consecutive couples attending the Miscarriage Clinic in Liverpool Their formula gives 
an estimate of the success rate of a subsequent pregnancy from weighting contribu­
tions of maternal age, menstrual cycle irregularity, previous live birth, number of 
previous miscarriages and presence of anticardiolipin antibodies 
Treatment 
Therapeutic intervention usually arises from the doctors' and couples' belief that the 
elimination of possible causes will improve subsequent pregnancy outcome This 
belief, however, should be based on proven favorable effects, established from well-
designed studies 
From the theoretical calculations of Malpas (1938) and Eastman (1946), it has been 
stated that a woman with three consecutive spontaneous abortions has a less than 
27% chance of achieving a successful pregnancy Studies on the efficacy of many 
Table 2.2. Success rates of the next pregnancy in women with recurrent miscarriage, as predic­
ted by obstetnc history including the number of previous miscarriages and live births, 
and maternal age 
Number of previous miscarriages 
2 
3 
4 
Number of previous 
0 
г 1 
Maternal age (y) 
21-30 
31-40 
>40 
live births 
Success rate* 
71 - 89% 
5 5 - 8 7 % 
4 4 - 6 4 % 
74 - 82% 
8 7 - 9 1 % 
71 - 86% 
49 - 74% 
2 5 - 6 0 % 
References! 
3 4,5,6,7 
2 3,4 5,6,7 
2.3,4,5 
1,2 
1 2 
2,5 
2,5 
2 5 
* Proportion of number of live births versus number of pregnancies, given as ranges, t In alphabetical 
order 1 Alberman 1988, 2 Cowchock and Smith, 1992, 3 Knudsen et al 1991, 4 Parazzini et al, 
1988, δ Quenby & Farquharson, 1993, 6 Regan, 1988, 7 Simpson et al, 1994 
8 Chapter 2 
Table 2.3. Success rates of the next pregnancy in untreated women with recurrent miscamage, 
as predicted by the presence or absence of potential etiologies (cases versus no-
cases, respectively) 
Potential etiology 
Uterine malformations 
Septate uterus 
Bicomuate uterus 
Endocnne disorders 
Hypersecretion of LHt 
Hyperandrogenism 
Oligomenorrhea 
Success rate* 
Cases 
53% 
5 1 % 
33%$ 
50% 
17%$ 
64%$ 
No-cases 
? 
? 
94% 
63% 
59% 
87% 
References 
Ludmiretal, 1990 
Ludmiretal, 1990 
Regan et al, 1990 
Tulppala et al, 1993b 
Tulppala et al, 1993b 
Quenby & Farquharson, 1993 
Immunological disorders 
Anticardiohpin antibodies 72%$ 78% Quenby & Farquharson, 1993 
Antmuclear antibodies 52% 66% Hargeretal, 1989 
Antithyroid antibodies 38%$ 86% Pratt et a l , 1993a 
High natural-killer cell activity 29%$ 80% Aokietal , 1995 
* Proportion of number of live births versus number of pregnancies, f Luteinizing hormone, t Signi­
ficantly different as compared to no-cases 
types of treatment have used this pessimistic figure for comparison Later clinical 
studies, however, have revealed that 60 - 75% of couples with unexplained recurrent 
miscarriage will achieve a subsequent successful pregnancy without any treatment 
[Vlaanderen and Treffers, 1987, Parazzini et a l , 1988, Houwert-De Jong et a l , 1989, 
Cowshock and Smith, 1992, Plouffe et a l , 1992, Tulppala et a l , 1993a] Therefore, 
many therapies that claimed moderate success rates, ι e up to 60%, might be incor­
rectly considered curative 
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Randomized, (placebo-)controlled trials are the "gold standard" by which medical 
interventions should be evaluated At present, few such trials have been performed 
among women with recurrent miscarriage (Table 2.4) The favorable effects of mater­
nal transfusion with paternal leukocytes seem controversial However, a recent meta­
analysis of nine randomized clinical trials on leukocyte immunization for treatment of 
recurrent spontaneous abortion has suggested a small but significant beneficial effect 
[The Recurrent Miscarriage Immunotherapy Tnalists Group, 1994] Treatment with 
hCG seems favorable in cases of oligomenorrhea, but additional trials are needed for 
reconfirmation before its use in clinical practice is advocated. 
Table 2.4. Randomized, placebo-controlled trials in women with recurrent miscarriage 
Treatment 
hCGt 
Progesterone 
Paternal 
leukocytes 
Trophoblast 
membranes 
Immunoglobulins 
Potential etiology 
Luteal phase deficiency 
Oligomenorrhea 
Luteal phase deficiency 
Alloimmunologtcal 
Alloimmunological 
Alloimmunological 
Success rate* 
Treatment 
83% 
85%φ 
76% 
73% 
80% 
62% 
61%t 
68% 
78% 
77%t 
33% 
74% 
Placebo 
85% 
40% 
84% 
50% 
76% 
76% 
44% 
47% 
65% 
37% 
50% 
70% 
References 
Harnson, 1992 
Quenby and Farquharson, 
1994 
Goldzieher, 1964 
LeVme, 1964 
Swyerfi. Daley, 1953 
Cauchietal, 1991 
Dayaetal, 1994 
Gatenbyetal, 1993 
Ho et al, 1991 
Mowbray et al, 1985 
Johnson et al, 1991 
The German RSA/IVIG 
Group, 1994 
* Proportion of number of live births versus number of pregnancies, t Human chononic gonadotropin, t 
Significantly different as compared to placebo 

Chapter 3 
HYPERHOMOCYSTEINEMIA: BIOCHEMICAL, 
(PATHOPHYSIOLOGICAL AND CLINICAL ASPECTS 
HOMOCYSTEINE METABOLISM AND ITS REGULATION 
Methionine is an essential sulfur-containing amino acid. Next to its use in protein 
synthesis, it can be converted to S-adenosylmethionine, a reaction which is catalyzed 
by methionine adenosyltransferase (enzyme commission, EC 2.5.1.6). S-adenosyl-
methionine is the primary methyl group donor in virtually all mammalian systems. S-
adenosylhomocysteine, the demethylated product of S-adenosylmethionine, is rever-
sibly hydrolyzed to adenosine and homocysteine, catalyzed by S-adenosylhomocys-
teine hydrolase (EC 3.3.1.1). Homocysteine is either irreversibly transsulfurated via 
cystathionine to cysteine, or remethylated to methionine (Figure 3.1) [Mudd et al., 
1989]. 
The conversion to cystathionine is catalyzed by the enzyme cystathionine ß-synthase 
(CBS; EC 4.2.1. 22) in a reaction requiring pyridoxal-5'-phosphate (PLP, an active 
form of vitamin B6) as a cofactor. Cystathionine is converted to cysteine, which can 
be further metabolized to taurine, sulfite and sulfate. In the remethylation of homo-
cysteine to methionine, the methyl group is donated by either 5-methyltetrahydrofola-
te or betaine. The methyl donation of 5-methyltetrahydrofolate results in the formation 
of tetrahydrofolate, catalyzed by 5-methyltetrahydrofolate-homocysteine methyltrans-
ferase (methionine synthase, MS; EC 2.1.1.13), which requires methylcobalamin 
(vitamin B12) as a cofactor. The transmethylation of betaine, catalyzed by betaine-
homocysteine methyltransferase (EC 2.1.1.5), results in the formation of N,N-di-
methylglycine. 
S-adenosylmethionine is an important regulator of the intracellular homocysteine 
concentration through its stimulation of CBS activity and its inhibition of 5,10-methyle-
netetrahydrofolate reductase (MTHFR; EC 1.1.1.68) activity (Figure 3.1) [Finkelstein, 
1990]. Lack of methionine, resulting in low S-adenosylmethionine concentrations, will 
reduce the transsulfuration of homocysteine to cystathionine, and enhance the 
remethylation of homocysteine to methionine. By contrast, excess methionine will 
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improve the t ranssudat ion and reduce the remethylation of homocysteine 
The extracellular homocysteine concentration, e g in serum or plasma, is determined 
by the formation, metabolism, and release of intracellular homocysteine In fact, 
homocysteine export reflects the balance between homocysteine production and 
utilization in the cell Therefore, plasma homocysteine may be an indicator of the 
activity of enzymic processes, or the availability of cofactors and substrates involved 
in intracellular homocysteine metabolism [Ueland and Refsum, 1989] 
S-ADENOSYLMETHIONINE TETRAHYDROFOLATE I 
BETAINE 
S-ADENOSYLHOMOCYSTEINE 
5,10-METHYLENE-
TETRAHYDROFOLATE 
MTHFR 
5-METHYL-
TETRAHYDROFOLATE 
HOMOCYSTEINE 
SERINE CBS 
У PYRIDOXALS'-PHOSPHATE 
CYSTATHIONINE 
HOMOSERINE 1 PYRIDOXALS'-PHOSPHATE 
CYSTEINE 
Figure 3.1. Simplified scheme of homocysteine metabolism, and enzymes and cofactors involved 
CBS Cystathionine ß-synthase, MS 5-Methyltetrahydrofolate-homocysteine methyl-
transferase (methionine synthase). MTHFR 5,10-Methylenetetrahydrofolate reducta-
se 
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DETERMINATION OF HOMOCYSTEINE IN BLOOD 
Different forms of homocysteine 
Homocysteine in blood is mainly (about 70%) bound in disulfides to proteins. A minor 
fraction constitutes of homocysteine-cysteine mixed disulfide and the disulfide homo-
cysteine-homocysteine (homocystine), and trace amounts of reduced homocysteine. 
Total homocysteine is defined as the sum of all homocysteine species liberated by 
reduction, including free and protein-bound forms. The plasma levels of various 
homocysteine species are related to the redox status and protein binding of other 
aminothiols, e.g. cysteine and cysteinylglycine, probably through disulfide exchange 
and displacement reactions [Mansoor et al., 1992]. Ex vivo, a continuous redistribu-
tion amongst homocysteine species increases the proportion that is protein-bound, at 
room temperature as well as in a frozen condition. The determination of free homo-
cysteine requires immediate precipitation of plasma proteins after blood sampling. 
Therefore, in the clinical setting and in studies based on stored samples, the 
measurement of total homocysteine is preferable [Ueland and Refsum, 1989]. 
Laboratory assay 
Several methods for the determination of total homocysteine in plasma or serum 
have been described. Most assays consist of four steps: 
(1 ) reduction of oxidized homocysteine species to thiols; 
(2) precolumn derivatization; 
(3) chromatographic separation; 
(4) quantification of the homocysteine derivative. 
The assay characteristics, instrument requirements, and performance of different 
methods and their modifications have recently been reviewed [Ueland et al., 1994]. 
Stability during storage 
To achieve a better standardization in the measurement of homocysteine, the effects 
of blood sample storage conditions on the concentrations of total homocysteine have 
been studied . These studies were performed in samples of whole blood and plasma. 
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In whole blood, the concentration of total homocysteine increases by 10% if stored at 
room temperature for about 1 hour, and by 4% if stored at 4°C for 4 hours [Anders-
son et al., 1992c; Ubbinket al., 1992; Fiskerstrand et al., 1993]. The increase of total 
homocysteine is presumably due to the continuous production of homocysteine in the 
erythrocytes, which is released to the extracellular compartment [Andersson et al., 
1992c]. However, samples of whole blood stored on crushed ice will remain stable for 
at least 6 hours [Kittner et al., 1995]. 
In plasma, total homocysteine concentrations vary within -6% and +6% if kept at 
room temperature for 14 days [Ubbink et al., 1992], and remain nearly constant for 
about 10 years if stored at -20°C [Israelsson et al., 1993]. 
Therefore, artificial increase in total homocysteine concentrations is minimalized if 
blood is put immediately on ice after collection, and plasma is prepared within a few 
hours and stored at -20°C. 
ASSESSMENT OF HOMOCYSTEINE STATUS 
Next to fasting, the homocysteine status may be assessed by the measurement of 
plasma homocysteine after oral methionine loading [Fowler et al., 1971]. This 
procedure involves the intake of a standard dose of L-methionine (0.1 g per kg body 
weight or 3.8 g per m2 body surface), and the determination of plasma homocysteine 
after a certain period of time, usually 4 or 6 hours. The response to methionine 
loading is expressed as the concentration of postmethionine plasma homocysteine or 
as the increase of plasma homocysteine above the fasting plasma homocysteine 
concentration. 
The concentration of plasma homocysteine in a fasting state, i.e. having low methio-
nine and S-adenosylmethionine concentrations, is supposed to reflect the capacity of 
homocysteine remethylation, whereas the concentration of plasma homocysteine 
after methionine loading, i.e. having high methionine and S-adenosylmethionine 
concentrations, may represent the capacity of homocysteine transsudation [Kang et 
al., 1992;Uelandeta!.. 1992]. 
Hyperhomocysteinemia has been variously defined by different investigators. It is 
generally described as abnormally elevated blood homocysteine concentrations, 
either fasting and/or after methionine loading. Cut-off values for blood homocysteine 
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are usually arbitrarily determined as the 95th percentile or mean plus two standard 
deviations for control subjects, or as the highest control value. 
PHYSIOLOGICAL DETERMINANTS OF HOMOCYSTEINE STATUS 
Gender, age, blood vitamins and renal function are well-known determinants of blood 
homocysteine in normal subjects. Several studies have demonstrated that blood 
homocysteine concentrations are significantly lower in premenopausal women as 
compared to men [Wilcken and Gupta, 1979; Boers et al., 1983; Blom et al., 1988; 
Fermo et al., 1993; Brattström et al., 1994; Jacobson et al., 1994]. The possible 
associations between blood homocysteine, and age, blood vitamins and serum crea-
tinine in normal subjects are summarized in Table 3.1. 
Table 3.1. Associations between blood homocysteine, either fasting or afíer methionine loading, 
and age, blood vitamins and serum creatinine in nonval subjects* 
Fasting homocysteine Postmethionine homocysteine 
Age 
Folate 
Vitamin B12 
Positive 
correlation 
1t,3t.4,5,7t,8t, 
9,11 
Negative 
correlation 
1,4,6,10t, 11 
1,4,6,9,1 Oí, 11 
Positive 
correlation 
Negative 
correlation 
3t 
PLP 1Φ.11 
Creatinine 2,4,7,10* 1t 
* Numbers indicate references in alphabetical order: 1. Andersson et al., 1992a; 2. Araki et al., 1989; 
3. Boers et al., 1983; 4. Brattström et al., 1994; S. Fermo et al., 1993; 6. Jacobsen et al., 1994; 7. Kang 
et al., 1986a; 8. Malinow et al., 1990; 9. Mòlgaard et al., 1992; 10. Pancharuniti et al., 1994; 11. Selhub 
et al., 1993; t Only women; $ Only men. 
Estrogens 
Women after menopause are hormonally characterized by low concentrations of 
serum 17ß-estradiol, and increased levels of follicle-stimulating hormone (FSH). In 
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premenopausal women, the serum concentrations of free homocysteine were 
demonstrated to be significantly lower than in postmenopausal women [Boers et al., 
1983; Brattström et al., 1985]. It was proposed that a uniquely efficient methionine 
metabolism may account for the lower incidence of vascular disease in women 
before menopause [Boers et al., 1983]. Kang et al. (1986a) have reported an abrupt 
increase of plasma homocysteine among women after 50 years of age, suggesting a 
negative relationship with hormonal changes after menopause. In a recent study, 
however, the plasma concentrations of homocysteine were independent of menopau-
sal status [Andersson et al., 1992a]. 
A statistically significant association between the concentrations of plasma homocys-
teine and serum 17ß-estradiol has not been established so far. The observation of 
reduced blood homocysteine concentrations in women during pregnancy, a condition 
which is characterized by a high concentration of circulating estrogens, is supportive 
to this hypothesis [Kang et al., 1986b; Andersson et al., 1992b]. Additionally, it was 
recently demonstrated that high fasting serum homocysteine concentrations may 
decrease by natural estrogen supplementation after menopause [Van der Mooren et 
al., 1994]. Synthetic estrogens, like ethinyl-estradiol in oral contraceptives, may affect 
homocysteine metabolism as well, although data are conflicting [Brattström et al., 
1992a; Steegers-Theunissen et al., 1992b]. 
Food intake 
Because methionine is a precursor of homocysteine, the methionine content of a 
meal may influence postprandial blood homocysteine concentrations. The data on 
possible variations in blood homocysteine due to food intake, however, are scarse 
and inconsistent. Total homocysteine concentrations in fasting and nonfasting 
plasma from 13 subjects were not significantly different [Malinow et al., 1989]. In six 
healthy subjects, excessive daily methionine intake (300% of normal) for 2 weeks 
was demonstrated to affect neither fasting nor postmethionine concentrations of 
plasma homocysteine [Andersson et al., 1990]. In another study, a small but signifi-
cant decrease in plasma total homocysteine was observed in 13 out of 15 volunteers 
within 4 hours after a normal breakfast [Ubbink et al., 1992]. A recent study has 
demonstrated that a protein-rich meal (protein content: about 51 g) leads to elevated 
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plasma homocysteine concentrations for at least 8 hours [Guttormsen et al., 1994]. 
The plasma elimination characteristeric of homocysteine (half-life time, 3-4 hours) 
may predict elevated plasma homocysteine concentrations for 12-20 hours following 
a protein-rich meal [Guttormsen et al., 1993; 1994]. This may implicate that the 
fasting concentration of plasma homocysteine is influenced by the protein content of 
dinner the day before. 
HOMOCYSTEINE AND VASCULAR DISEASE 
Gibson and co-workers (1964) were the first to describe pathological vascular 
changes in homocystinuria. In 1975, McCully formulated the homocysteine theory of 
arteriosclerosis. It was pointed out that the high concentrations of homocysteine may 
be responsible for the premature vascular lesions in homocystinuria. This theory 
implies that mild hyperhomocysteinemia might be a factor in the pathogenesis of 
arteriosclerosis. 
Homocystinuria 
Homocystinuria is characterized by massive urinary excretion of homocysteine and 
severe elevation of blood homocysteine and methionine concentrations [Mudd et al., 
1989]. The classical form is due to homozygosity for CBS deficiency [Mudd et al., 
1985]. CBS deficiency is inherited in an autosomal recessive fashion and demonstra-
tes marked clinical heterogeneity. In somatic cell hybrids, the CBS gene was 
demonstrated to be localized to chromosome 21 [Skovby et al., 1984]. Its cDNA has 
been cloned and mapped [Kraus et al., 1993]. In CBS deficient patients, several 
mutations have been characterized. Homocystinuria due to homozygosity for CBS 
deficiency is clinically characterized by mental retardation, ectopia lentis, skeletal 
abnormalities, and vascular disease including premature arteriosclerosis, and arterial 
and venous thromboembolism. 
Obligate heterozygotes for classic homocystinuria, i.e. parents or children of patients 
suffering from homocystinuria due to homozygosity for CBS deficiency, have 
increased plasma homocysteine concentrations as compared to normal controls, but 
not as high as the concentrations found in homocystinuric patients [Sardharwalla et 
al., 1974; Boers et al., 1985a; Clarke et al., 1991]. It is controversial whether hetero-
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zygosity for CBS deficiency is associated with premature vascular disease. A survey 
of parents and grandparents of children with severe CBS deficiency failed to demon-
strate a significant increase in the incidence of vascular disease [Mudd et al., 1981]. 
Ultrasound examinations of systemic arteries have revealed controversial results 
regarding a possible relationship between heterozygosity for CBS deficiency and 
asymptomatic vascular disease [Rubba et al., 1990; Celermajer et al., 1993]. 
Rare forms of homocystinuria originate from defects in the remethylation pathway, 
i.e. MTHFR deficiency resulting in inadequate supply of 5-methyltetrahydrofolate, or 
defects in methylcobalamin synthesis leading to impaired methyl transfer (Figure 3.1) 
[Rosenblatt, 1989; Fenton and Rosenberg, 1989]. The vascular changes observed in 
homocystinuria due to remethylation defects are very similar to those in CBS 
deficiency, suggesting that high concentrations of homocysteine itself induce 
vascular lesions [McCully, 1975]. 
Mild hypertiomocysteinemia in vascular patients 
Many patient-control studies have demonstrated that mild hyperhomocysteinemia, in 
which the elevated blood homocysteine concentrations are comparable to those of 
obligate heterozygotes for CBS deficiency, is associated with an increased risk of 
premature vascular disease. Most of these studies have been recently reviewed 
[Kang et al., 1992; Ueland et al., 1992]. Table 3.2 summarizes the reported frequen-
cies of mild hyperhomocysteinemia, either fasting or after methionine loading, among 
vascular patients and controls. 
In cross-sectional studies, the blood homocysteine concentrations are associated 
with the degree or extent of cardiovascular disease. In this respect, it has been 
demonstrated that higher concentrations of homocysteine are positively correlated 
with the number of main coronary arteries with severe stenosis [Ubbink et al.,1991; 
Von Eckardstein et al., 1994], and the degree of wall thickening and stenosis of 
carotid arteries [Malinow et al., 1993; Seihub et al., 1995]. 
Due to their design, retrospective studies cannot determine whether hyperhomocys-
teinemia is the cause or the result of premature arterial disease. Prospective studies 
do not have this limitation. A prospective study of 271 healthy male physicians and 
their matched controls has demonstrated a significantly increased relative risk of 
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Table 3.2. Frequencies of elevated blood homocysteine concentrations, either fasting or after 
methionine loading, in vascular patients and controls' 
Elevated 
blood 
homocysteine 
Cerebro-
vascular 
disease 
Peripheral 
arterial 
disease 
Coronary heart 
disease 
Venous 
thromboembolic 
disease 
Controls 
Fasting 
Referencest 
Postload 
Referencest 
23 - 47% 
2,3,5,7,14 
24-42% 
1,2,3,6,9,11 
20 
23 - 47% 
3,14,16,18 
17-38% 
1,3,6,9,11 
20 
10-42% 
12,13,15,17 
19,22,23 
0 - 30% 
1,6,9,13,17 
20,21,22 
9 - 25% 
4,8,10 
14 - 24% 
4,8,10 
2 -10% 
2-10% 
* Presented as ranges, t In alphabetical order 1 Boers et al, 1985b, 2 BrattstrOm et al, 1984, 3 
BrattstrOm et al ,1990, 4 BrattstrOm et al, 1991, 5 BrattstrOm et al ,1992b, 6. Clarke et al, 1991, 7 
Coull et al, 1990, 8. Den Heijer et al, 1995, 9. Dudman et al, 1993, 10 Falcon et al, 1994; 11. 
Franken et al, 1994b, 12. Genestetal, 1990; 13 Israelsson et al., 1988, 14 Malinowetal, 1989, 15. 
Malmow et al., 1990, 16 MOIgaard et al, 1992; 17 Murphy-Chutonan et al., 1985, 18. Taylor et al., 
1991; 19 Ubbmk et al, 1991, 20. Van den Berg et al, 1994, 21 Wilcken and Wìlcken, 1976, 22. 
Wilcken et al., 1983. 23. Williams et al., 1990 
myocardial infarction within five years (RR = 3.1, 95% confidence interval 1 4 - 6 9) in 
subjects with elevated plasma homocysteine concentrations as compared to those 
with normal concentrations [Stampfer et al., 1992]. In a recent prospective study of 
109 healthy physicians and 427 control subjects, a small but nonsignificant associa-
tion between elevated concentrations of plasma homocysteine and the risk of ische-
mic stroke was observed [Verhoef et al., 1994] By contrast, in a prospective popula-
tion-based study of 265 Finnish subjects and their age- and sex-matched controls, no 
association was found between the serum concentrations of homocysteine and the 
incidence of myocardial infarction or stroke [Alfthan et al., 1994]. 
Etiology of mild hypertiomocysteinemia in vascular patients 
Disorders of the transsudation or remethylation of homocysteine may result in 
hyperhomocysteinemia. Enzymatic defects as well as vitamin deficiencies may inter-
fere with both routes [Mudd et al., 1989]. 
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Transsulfuration disorders. Heterozygosity for CBS activity has been proposed as a 
cause for mild hyperhomocysteinemia in patients with vascular disease. Two studies 
have confirmed an intermediate enzyme deficiency, i.e. within the range of enzyme 
activities of obligate heterozygotes, in cultured fibroblasts from the majority of 
hyperhomocysteinemic vascular patients [Boers et al., 1985b; Clarke et al., 1991]. 
The consistent identification of patients with vascular disease as heterozygotes for 
CBS deficiency is troubled by the wide range of CBS activities found in controls 
overlapping with the range of those in obligate heterozygotes [Boers, 1994]. This may 
be due to the large degree of heterogeneity among mutant alleles for CBS [McGill et 
al., 1990]. A recent molecular study of the CBS coding region in four vascular 
patients with hyperhomocysteinemia and reduced CBS activity did not reveal any mu-
tation previously identified in heterozygous carriers and homocystinuric patients 
[Kozichetal., 1995]. 
Recently, CBS activities of cultured fibroblasts from 15 vascular patients with 
hyperhomocysteinemia and 31 healthy controls were reported to vary over wide 
ranges and to have a substantial overlap, although the mean CBS activity of patients 
was significantly lower than the mean of controls [Dudman et al., 1993]. In another 
recent study, CBS activities were within the normal range and higher than heterozy-
gote levels in 9 out of 10 hyperhomocysteinemic patients with vascular disease, in-
dicating that decreased CBS activity is not a major cause of hyperhomocysteinemia 
in patients with premature vascular disease [Engbersen et al., 1995]. 
Since PLP is a cofactor of CBS, deficiency of PLP may result in hyperhomocysteine-
mia. Vitamin B6 deficiency has been observed to increase the concentrations of 
homocysteine after methionine loading, in plasma [Miller et al., 1994] as well as urine 
[Park and Linkswiler, 1970; Shin and Linkswiler, 1974]. In a fasting state, however, 
vitamin B6 deficiency does not result in an elevation of plasma homocysteine [Miller 
et al., 1992; Miller et al., 1994] or urinary homocysteine excretions [Park and Links-
wiler, 1970; Shin and Linkswiler, 1974]. These observations may be explained by a 
disruption of the coordinate regulation of homocysteine metabolism by S-adenosyl-
methionine. As previously stated, S-adenosylmethionine is an activator of CBS 
activity and an inhibitor of MTHFR activity [Finkelstein, 1990]. It is hypothesized that 
in a fasting state, vitamin B6 deficiency inhibits homocysteine transsulfuration without 
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affecting its remethylation to methionine, resulting in normal homocysteine concentra-
tions. After methionine loading, increased levels of S-adenosylmethionine may 
additionally lead to the inhibition of homocysteine remethylation, resulting in elevated 
homocysteine concentrations [Finkelstein, 1990; Selhub and Miller, 1992]. 
Remethylation disorders. Thermolabile MTHFR is another possible cause of hyperho-
mocysteinemia in vascular patients. This variant of MTHFR deficiency is characteri-
zed by a specific activity of about 50% of the normal enzyme activity, and a residual 
activity after in vitro heat inactivation of less than 30%, compared to 50% residual 
activity in normal controls [Kang et al., 1988a; 1988b; 1991]. The prevalence of 
thermolabile MTHFR in 212 coronary artery patients has been reported as 17% 
[Kang et al., 1991]. However, hyperhomocysteinemia was not a common finding 
among patients with thermolabile MTHFR. In a recent study, thermolabile MTHFR 
was established in 11 of 39 hyperhomocysteinemic patients with premature vascular 
disease [Engbersen et al., 1995]. 
The human gene for MTHFR is localized to chromosome 1. Its cDNA was isolated by 
Goyette et al. (1994). Recently, a common mutation in the MTHFR coding sequence, 
which correlates with reduced activity and increased thermolability of the enzyme in 
lymphocyte extracts, was identified. A significant elevation in plasma homocysteine 
was observed in individuals who were homozygous for this mutation [Frosst et al., 
1995]. 
Folate and vitamin B12 are involved in the remethylation of homocysteine (Figure 
3.1) [Rosenblatt, 1989; Fenton and Rosenberg, 1989]. Therefore, folate and vitamin 
B12 deficiency may cause increased blood homocysteine concentrations. Indeed, 
elevated homocysteine levels have been reported in subjects with folate or cobalamin 
deficiency [Kang et al., 1987; Brattstròm et al., 1988b; Stabler et al., 1988; Savage et 
al., 1994]. Methylmalonic acid, a metabolite of cobalamin metabolism, and total 
homocysteine are sensitive screening tools for diagnosing folate and cobalamin 
deficiencies [Savage et al., 1994]. Conversely, vitamin deficiency is a common 
finding in hyperhomocysteinemic subjects. In a large study of an elderly population, 
aged 67 to 96 years, it appeared that a marginal or manifest vitamin deficiency 
contributed to two-third of the cases of high plasma homocysteine [Selhub et al., 
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1993]. In a study of 44 apparently healthy men with moderate hyperhomocysteine-
mia, almost 60% had a suboptimal folate or cobalamin status [Ubbink et al., 1993]. 
In folate-deficient rats, it was recently demonstrated that the plasma homocysteine 
concentrations after methionine loading did not significantly differ from the elevated 
concentrations at baseline [Miller et al., 1994]. Disruption of the coordinate regulation 
of homocysteine metabolism by S-adenosylmethionine may provide an explanation 
for this observation. It is thought that, in a fasting state, folate deficiency inhibits 
homocysteine remethylation. As a consequence, decreased synthesis of S-adenosyl-
methionine may reduce homocysteine transsulfuration as well, resulting in elevated 
concentrations of homocysteine. After methionine loading, increased synthesis of S-
adenosylmethionine stimulates homocysteine transsulfuration, which may balance 
the homocysteine increase due to methionine loading [Finkelstein, 1990; Selhub and 
Miller, 1992]. 
Pathogenesis of vascular disease in mild hyperhomocysteinemia 
Homocysteine is generally held to be an atherogenic 'and thrombotic agent, although 
the exact pathophysiological sequence has not been clarified. Abnormalities of 
endothelial cells, platelets, clotting factors, serum lipids, or disorders in the complex 
interaction of these factors have been held responsible for the vascular damage and 
thrombogenesis in hyperhomocysteinemia [Mudd et al., 1989; Kang et al., 1992; 
Ueland et al., 1992]. The possible modes of action are summarized in Table 3.3. 
Homocysteine-lowering treatment 
Theoretically, the administration of vitamin B6 may enhance the homocysteine 
transsulfuration, whereas the supplementation of folic acid, vitamin B12 and/or 
betaine possibly improves the remethylation to methionine. Thus, vitamin treatment 
may reduce elevated plasma homocysteine concentrations. 
Homozygotes for homocystinuria respond in about 50% of cases to pyridoxins 
treatment in doses up to 1 g daily. Treatment with folic acid, betaine or dietary 
methionine restriction may result in a reduction of homocysteine levels in the majority 
of poor- or non-responders to pyridoxine [Mudd et al., 1985]. 
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Table 3.3. Possible modes of action of homocysteine as related to its effect on atherosclerosis 
and thrombosis 
Mode of action Original references 
Vascular endothelium 
Endothelial desquamation 
Intimai proliferation of smooth muscle cells 
Hydrogen peroxide formation 
Reduced prostacyclin formation 
Reduced thrombomodulin surface expression 
Increased tissue factor activity 
Reduced von Willebrand factor secreten 
Impaired production of relaxation factor and nitnc oxide 
Harkeret a l , 1974,1976 
Harker et a l , 1974, 1976 
Starkebaum and Harlan, 1986 
Panganamala et a l , 1986 
Lente and Sadler, 1991 
Fryer et a l , 1993 
Lente and Sadler, 1993 
Stamleretal, 1993 
Platelets 
Increased turnover, decreased survival time 
Increased formation of thromboxane 
Harkeret a l , 1974, 1976 
Graeberetal, 1982 
Clotting factors 
Reduced antithrombm ill activity 
Reduced factor VII activity 
Increased factor V activity 
Reduced protein С activity 
Giannini et a l , 1975 
Merckx and Kuntz, 1981 
Rodgers and Kane, 1986 
Rodgers and Conn, 1990 
Serum lipids 
Oxidation of low-density lipoproteins 
Binding of lipoprotem(a) to fibnn 
Heinecke et a l , 1987 
Parthasarathy, 1987 
Harpeletal, 1992 
Pyndoxine treatment has been studied in vascular patients with mild hyperhomocys-
teinaemia [Boers et a l , 1988, Brattström et a l , 1990, Dudman et a l , 1993, Franken 
et al , 1994], as well as in healthy subjects with normal homocysteine concentrations 
[Brattstrom et a l , 1988a] It has been demonstrated that pyndoxine treatment 
normalizes the response to methionine loading in more than 50% of vascular patients 
with mild hyperhomocystememia [Franken et a l , 1994] Pyndoxine treatment, howe-
ver, does not result in a significant decrease of fasting homocysteine concentrations 
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[Brattström et al., 1990]. 
Folic acid has been reported as an effective means to reduce the elevated plasma 
concentrations of homocysteine in patients with chronic renal insufficiency [Wilcken 
et al., 1988], in uremic patients on chronic dialysis [Arnadottir et al., 1993], and in 
renal transplant recipients [Wilcken et al., 1981]. Recently, folic acid treatment was 
demonstrated to be effective in vascular patients with impaired homocysteine 
metabolism [Dudman et al., 1993; Franken et al., 1994]. In healthy subjects, normal 
levels of blood homocysteine were also lowered by folic acid supplementation 
[Brattström et al., 1985; 1988a]. 
From a study of 421 patients with vascular disease, it was concluded that vitamin B6 
(250 mg daily), folic acid (5 mg daily), and betaine (6 g daily) solely or in any 
combination led in virtually all treated hyperhomocysteinemic patients to normaliza-
tion of their overresponse by homocysteine to methionine loading [Franken et al., 
1994]. Similarly, the combined administration of pyridoxine, 250 mg daily, and folic 
acid, 5 mg daily, reduced the elevated plasma homocysteine concentrations of 66 out 
of 72 young patients with arteriosclerosis [Van den Berg et al., 1994]. 
Unfortunately, most studies have been performed without placebos or controls. 
Recently, the homocysteine-lowering effects of folic acid, 0.65 mg daily, pyridoxine, 
10 mg daily, cyanocobalamin, 0.4 mg daily, and a combination of the three vitamins 
were compared in a placebo-controlled trial of 100 hyperhomocysteinemic men 
[Ubbink et al., 1994]. A significant decrease in plasma homocysteine concentrations 
was observed in men supplemented with folic acid, cyanocobalamin, and the 
combination of vitamins (-42%, -15%, and -50%, respectively). The authors sugge-
sted that effective treatment of hyperhomocysteinemia should include at least a 
combination of folic acid and vitamin B12 [Ubbink et al., 1994]. 
The effect of vitamin treatment on the occurrence and recurrence of vascular disease 
in patients with hyperhomocysteinemia is yet unknown, and needs to be established 
by appropiate clinical trials. 
HOMOCYSTEINE AND ADVERSE PREGNANCY OUTCOME 
Fetal loss has been observed in 25 of 52 pregnancies of untreated homozygous, 
CBS deficient women. This data, however, was strongly influenced by the high 
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number of stillbirths and spontaneous abortions in a few individuals [Mudd et al., 
1985]. A high perinatal mortality rate (3 out of 30 pregnancies) due to stillbirth, 
neural-tube defect (NTD) and prematurity has been reported in eight women who 
were obligate heterozygotes for homocystinuria [Burke et al., 1992]. 
Preliminary studies have suggested an association between increased postmethioni-
ne serum homocysteine concentrations and adverse pregnancy outcome, i.e. NTD, 
recurrent spontaneous abortion, and placental abruption [Steegers-Theunissen et al., 
1990a; 1992a]. Part of this observation was recently confirmed in a study of 41 
women with NTD-affected pregnancies demonstrating significantly elevated mean 
plasma homocysteine concentrations, before as well as after methionine loading, as 
compared to 50 controls [Steegers-Theunissen et al., 1994]. In addition, it was 
recently reported that mothers of children with NTD had significantly higher homocys-
teine values than vitamin B12-matched controls [Mills et al., 1995]. In another study, 
however, fasting concentrations of plasma homocysteine were not significantly 
different between women with intrauterine growth retardation and controls, whereas 
postmethionine levels had not been measured [Burke et al., 1992]. 
The mechanism how elevated concentrations of blood homocysteine may disturb 
normal pregnancy development is not yet understood. Theoretically, homocysteine 
may act as an atherogenic and thrombotic agent in placental, umbilical and embryo-
nic vessels. Microthrombosis, vasospastic changes, fibrin depositions, and necrosis 
are common morphologic features in tissue specimens from spontaneous abortion 
and placental infarction [Rushton, 1988; Rayne and Kraus, 1993]. A second mecha-
nism by which abnormally high homocysteine levels may disturb normal pregnancy 
outcome is embryotoxicity. Recently, a high concentration of L-homocysteine (4 mM) 
was demonstrated to be toxic to rat embryos in vitro. In lower concentrations (1 or 2 
mM), however, the addition of L-homocysteine was not toxic and promoted normal 
development of the rat embryos in serum that without supplementation caused NTDs 
in the embryos. Interestingly, L-methionine had the same beneficial effect at even 
lower concentrations, and the embryotoxic effect of L-homocysteine was attenuated 
by the addition of L-methionine [Van Aerts et al., 1994]. Methionine is the precursor 
of S-adenosylmethionine, which is the universal methyl group donor in transmethyla-
tion reactions and thus essential to normal embryonic growth and development. As a 
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low ratio of S-adenosylmethionine and S-adenosylhomocysteine will inhibit many 
transmethylation reactions [Cantoni et al., 1978], it is hypothesized that increased S-
adenosylhomocysteine formation resulting from high concentrations of homocysteine 
is the first step in the embryotoxic mechanism of L-homocysteine [Van Aerts et al., 
1994]. 
As discussed earlier, mild hyperhomocysteinemia may result from transsudation 
and/or remethylation defects. In hyperhomocysteinemic women with NTD-affected 
children, however, the activities of CBS in cultured fibroblasts were within the normal 
range [Steegers-Theunissen et al., 1994]. The authors have suggested an acquired 
or inherited defect of the remethylation to methionine as the cause of hyperhomocys-
teinemia in NTD. Their view is in line with the observation that L-methionine deficien-
cy induced NTD in cultured rat embryos [Coelho et al., 1989; Coelho and Klein, 
1990]. In addition, a recent study exploring a common mutation in the MTHFR gene 
has revealed significantly higher prevalences of homozygosity for this mutation in 
NTD affected children and their mothers [Van der Put et al., 1995]. Individuals 
homozygous for the mutation had significantly reduced MTHFR activities, elevated 
plasma homocysteine, and decreased plasma folate concentrations. This data sug-
gests that the mutation is a genetic risk factor for NTD [Van der Put et al., 1995]. 
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OBJECTIVES, DESIGN AND LABORATORY METHODS 
INTRODUCTION 
The studies presented in this thesis were performed at the outpatient clinic of the 
Department of Obstetrics and Gynecology, University Hospital Nijmegen St Radboud, 
Nijmegen, The Netherlands. Studies were approved by the ethical committee of the 
hospital (Commissie Experimenteel Onderzoek met Mensen, 9106-4502). Written 
informed consent was obtained from all women before participation. 
OBJECTIVES 
1. To compare the concentrations of plasma homocysteine in premenopausal 
and postmenopausal women with normal pregnancy outcome, and to exami-
ne a possible relationship between the homocysteine and estrogen status. 
2. To establish the prevalence of hyperhomocysteinemia in women with recur-
rent miscarriage, and to examine the association between the homocysteine 
and vitamin status in these women. 
3. To estimate the prevalence of reduced cystathionine ß-synthase (CBS) 
activity and thermolabile 5,10-methylenetetrahydrofolate reductase (MTHFR) 
in hyperhomocysteinemic women with recurrent miscarriage. 
4. To evaluate the effects of pyridoxine and folic acid treatment on elevated 
plasma homocysteine concentrations in women with adverse pregnancy 
outcome. 
5. To evaluate prospectively the effect of periconceptional B-vitamin treatment 
on the outcome of the next pregnancy in women with recurrent miscarriage. 
6. To compare the homocysteine status of women with recurrent miscarriage 
before and after a subsequent pregnancy. 
7. To establish the prevalence of hyperhomocysteinemia in women with a 
history of placental vasculopathy, i.e. abruption or infarction of the placenta. 
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DESIGN 
Selection and screening procedure 
Forty-six premenopausal (group la) and 26 postmenopausal women (group lb) with 
normal pregnancy outcome were recruited by public advertisement. One hundred 
and ninety-two women with recurrent miscarriage (group II) were referred to the 
hospital by their general practioner, midwife or gynecologist. Selection criteria were 
formulated at the beginning of the study (Table 4.1 ). All women underwent a standar-
dized screening procedure (Table 4.2). 
Twelve women with recurrent miscarriage were excluded from final analysis because 
they did not fulfill the selection criteria: parental chromosomal translocation (n = 7), 
septate (n = 1 ) or bicomuate uterus (n = 2), and presence of anticardiolipin antibodies 
(n = 2). All women (£n = 46 + 26 + 180 = 252) were tested by oral methionine loa-
ding test. 
Oral methionine loading test (all groups) 
Women were not pregnant at the time of the investigation. They were not allowed to 
take oral contraceptives, hormonal or vitamin supplements, or any other medication 
that could possibly interfere with homocysteine metabolism for at least three months 
prior to the study. 
After an overnight fast, venous blood samples were drawn to measure the concentra-
tions of plasma homocysteine, serum and red cell folate, serum vitamin B12, and 
whole blood pyridoxal-5'-phosphate (PLP). Then L-methionine, 0.1 g (0.7 mmol) per 
kg bodyweight was administered orally in 200 mL of orange juice (total content of 
folic acid, 80 yg). All women used a standardized methionine-restricted breakfast and 
luncheon (total content of 14 mg methionine in 2 g of proteins, 95 g of carbohydrates, 
and 31 g of fats; total energy load of 2.8 kJ). No drinks, except for coffee and tea 
without milk were allowed during the test period. Six hours after methionine loading, 
venous blood was collected for the measurement of postmethionine plasma homo-
cysteine. Hyperhomocysteinemia was defined as a fasting and/or postmethionine 
plasma homocysteine concentration above the estimated 97.5 percentile level of 
premenopausal women with normal pregnancy outcome. 
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Table 4.1. Selection criteria as formulated at the beginning of the study 
Group la Group lb Group II 
Inclusion criteria 
Л/orma/ pregnancy outcome 
At least one healthy child 
No miscarriages 
No fetal loss 
No neural tube defect 
No placental pathology 
Normal pregnancy outcome 
At least one healthy child 
No miscarriages 
No fetal loss 
No neural tube defect 
No placental pathology 
Recurrent miscarriage 
Two or more consecutive miscarria­
ges* with the same partner 
Premenopausal 
Menses every 3 - 6 weeks 
Postmenopausal 
No menses for >1 year 
FSH > 36 U/Ltt 
17ß-Estradk>l s 150 pmol/Lt 
Premenopausal 
Menses every 3 - 6 weeks 
No history of liver, renal or 
vascular disease 
No history of liver, renal or 
vascular disease 
No history of liver, renal or vascular 
disease 
Exclusion criteria 
Risk factors for recurrent miscarriage: 
Chromosomal translocations 
Uterine abnormalities 
Septate 
Bicornuate 
Immunologic disorders 
Lupus anticoagulant 
Anticardiolipin antibodies 
* Defined as spontaneous pregnancy loss within 16 weeks of amenorrhea, as confirmed by positive 
routine urinary human chorionic gonadotropin (hCG) test, and/or ultrasound imaging of at least one 
intrauterine gestational sac, with or without positive heartbeat, and/or histologic evidence of pregnancy; 
t Follicle stimulating hormone; t Routine laboratory standards (Laboratory of Endocrinology and 
Reproduction, Department of Obstetrics and Gynecology, University Hospital Nijmegen St Radboud). 
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Table 4.2. Standardized screening procedure 
History-taking 
Personal 
Gynecologic 
Obstetric 
Cardiovascular 
Life-style habits 
Family 
Physical examination 
Length and weight 
Blood pressure 
Blood sampling 
Complete blood count 
Liver and renal profile 
Glucose 
Hormonal 
17ß-Estradiol, progesterone 
Follicle stimulating hormone (FSH) 
Immunologic 
Lupus anticoagulant t§ 
AnticardJolipin antibodies $§ 
Karyotyping 
Additional procedures* 
Ultrasound 
Hysterosalpingography 
Hysteroscopy 
Group la 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Group lb 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Group II 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
* To exclude uterine abnormalities, either alone or in combination; f Kaolin-clotting time, 1:5 dilution of 
patients' samples in phospholipid-free substrate plasma; t Standardized enzyme-linked immunosor-
bent assay (ELISA); § Routine laboratory standards (Laboratory of Hematology, University Hospital 
Nijmegen St Radboud). 
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Enzyme studies (group II) 
The activities of CBS were measured in cultured fibroblasts of seven women with 
hyperhomocysteinemia. Thermolabile MTHFR was determined in the isolated lym­
phocytes of 17 women with hyperhomocysteinemia. 
Homocysteine-lowering treatment (group II) 
Nineteen hyperhomocysteinemic women were treated with either pyridoxine, 250 mg 
daily, or folic acid, 1 or 5 mg daily, and their homocysteine status was reevaluated by 
methionine loading test at least four weeks after the start of treatment. 
Subsequent pregnancy outcome (group II) 
The outcome of the first pregnancy after study entry was evaluated in 142 women as 
related to their initial homocysteine status and periconceptional B-vitamin use. 
Longitudinal observation of homocysteine status (group II) 
Seventeen women with recurrent miscarriage were reexamined by oral methionine 
loading test after the completion of a subsequent pregnancy. 
LABORATORY METHODS 
Homocysteine 
Blood samples for the quantitation of plasma total homocysteine were drawn in 
ethylenediamine tetraacetate (EDTA) vacutainer tubes, and centrifugea within 30 
minutes at 3000 χ g for 10 minutes. The plasma was separated and stored at -20°C 
until analysis. 
Total homocysteine concentrations (free and protein-bound) were measured by high-
performance liquid chromatography (HPLC) technique with reverse phase separation 
and fluorimetrie detection (Gilson 232-401 sample processor, Gilson Medical Electro­
nics, Inc., Middleton, Wl; SP8800 solvent delivery system and SP LC-304 fluorome-
ter, Spectra Physics, San Jose, CA) [Fiskerstrand et al., 1993; Te Poele-Pothoff et 
al., 1995]. This method is based on complete reduction of all homocysteine disulfide 
bounds in plasma by sodiumborohydride and dithioerythritol. After derivatization by 
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monobromobimane the resulting fluorescent homocysteine-monobromobimane 
complex is separated from interfering substances by reverse phase chromatography. 
For derivatization 30 μ ι of plasma was mixed with 30 μΙ_ of 4 mol/L NaBH4 in 0.066 
mol/L NaOH and 333 ml_/L dimethylsulfoxide, 10 μ ι of 2 mmol/L EDTA and 1.65 
mmol/L dithioerythritol and 0.1 mmol/L cysteamine (as an external standard), 10 μ ι 
of 1-octanol, and 20 μ ι of 1.8 mol/L HCl. After 3 minutes, 100 μ ι of 1.5 mol/L ethyl-
morpholine buffer, 400 μ ι of H20, and 20 μ ι of 25 mmol/L monobromobimane were 
added. The derivatization with monobromobimane was terminated after 3 minutes by 
adding 40 μ ι of glacial acetic acid. 
For separation a 20 μ ι aliquot of the derivatized sample was injected on a supelcosil 
LC-18 column (150 χ 4.6 mm, 3 μπτι, Supelco Inc., Bellefonte, PA), equilibrated with 
30 mmol/L ammonium nitrate, 40 mmol/L ammonium formate, and 5 mmol/L tetrabu-
tylammoniumhydrogen sulfate, pH 3.4. Four minutes after injection homocysteine 
was eluted of the column with a gradient of θ to 11% acetonitrile with a flow rate of 1 
mL/min. The retention time of homocysteine was about 12 minutes. Recovery of 
homocysteine added to plasma was about 95%. The lower limit of detection was 0.5 
μπ-iol/L. The intraassay and interassay coefficients of variation were 2.1% and 5.2%, 
respectively [Te Poele-Pothoff et al., 1995]. 
Folate and vitamin B12 
The concentrations of folate and vitamin B12 were determined simultaneously by 
using Dualcount SPB (Solid Phase Boil) Radioassay (Diagnostic Products Corpora­
tion, Los Angeles, CA, USA) [Steegers-Theunissen et al., 1990b]. The method inclu­
des a heat denaturation step of endogenous protein (15 minutes at 100°C, pH 9.3) of 
the unknown samples and the calibrators (zero dose standard and six calibrators 
containing 1 to 55 nmol folate and 40 to 1800 pmol vitamin B12 per liter of a protein 
matrix). At this stage the dual label tracer solution (125l folate and97Co cyanocobala-
min) was added. It contained dithiothreitol and potassium cyanide (pH 9.3) to release 
the vitamin B12 and folate in the sample from carrier proteins. Next, a suspension of 
the solid phase binders for folate and vitamin B12 (ß-lactoglobulin and purified hog 
intrinsic factor respectively, coated onto microcrystalline cellulose particles) was 
added and incubated for 60 minutes at room temperature and pH 9.3. At this pH, 
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intrinsic factor is fully active and the folate binder has equal affinity for 5-methyl-
tetrahydrofolate and its stable form, pteroylglutamic acid (also used as the calibrator 
preparation). Following bound-free separation by centrifuging (15 minutes at 3000 χ 
g) and decanting the supemate, the radioactivity of the bound (precipitate) fraction 
was counted and the quantitation of the analytes was performed using a logit-log 
algorithm (Ria Cale, Wallac Oy, Turku, Finland). 
Red cell folate concentrations were calculated from folate measurements in heparini-
zed blood hemolysate and plasma. Hemolysates were made in three dilutions in 
assay buffer (21 x, 10x, and 5x) to which 1% ascorbic acid was added. The calcula­
tion was done according to the equation: 
RCF = [DF χ HF - PF χ ( 1 - Ht )] / Ht 
RCF = red cell folate [nmol/L]; DF = dilution factor; HF = hemolysate folate [nmol/L]; 
PF = plasma folate [nmol/L]; Ht = hematocrit [L/L]. 
The minimum detectable concentration of red cell folate thus calculated was 4Θ 
nmol/L since the lowest detectable plasma folate concentration was 1.1 nmol/L and 
the highest hematocrit found was 0.48. The minimum detectable serum vitamin B12 
concentration was 40 pmol/L as calculated at the B/B0 response level of 0.90. 
Intra-assay and inter-assay variabilities for means of duplicate determinations were 
calculated from 24 consecutive assay runs with two different plasma pools. At mean 
pool folate concentrations of 20 and 40 nmol/L and vitamin B12 concentrations of 540 
and 800 pmol/L the intraassay and interassay coefficients of variation were always 
below 5% and 10%, respectively, for each of both vitamins. 
Vitamin B6 
The determination of vitamin B6 as pyridoxal-5'-phosphate (PLP) was performed by 
HPLC [Steegers-Theunissen et al., 1992b]. This technique was first described by 
Schrijver et al. (1981). In brief, the procedure involved the following steps which 
included several modifications concerning the denaturation of whole blood and fluids, 
the mobile phase and the HPLC column used. To 1 mL of heparinized blood 1 mL of 
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1.2 mol/L perchloric acid was added and the supernatant was collected after centrifu­
garon at 1000 χ g for 10 minutes. To 0.5 mL of the supernatant 0.05 mL of a 4.4 
mol/L potassium hydroxide solution was added and the supernatant was collected 
after centrifugation at 1000 χ g for 10 minutes. With an automated sampler (Wisp 
710B, Waters Associates, Millipore Corporation, Milford, MA, USA) 0.2 mL of the 
supernatant was injected on a Microbondapack C18 Radial Pak θ mm column with a 
Guard Pak pre-column (Waters) equipped to an automatic HPLC pump (Model 590, 
Waters). The mobile phase comprised a 0.025 mol/L citrate buffer (pH 2.7) containing 
20 mg/L of hexane sulfonate (FSA Laboratory Supplies, Loughborough, England). 
Postcolumn derivatization according to Schrijver et al. (1981) was performed with 
semicarbazide reagent to obtain the PLP semicarbazone. By using wavelenghts for 
excitation (367 nm) and emission (478 nm) the fluorescence was determined with a 
Shimadzu RF-5000 fluorospectrophotometer (Shimadzu Corporation, Tokyo, Japan) 
equipped with a 12 μ ι HPLC cell and connected to an integrator (Shimadzu CR5A) 
for calculation of the whole blood concentrations. Linearity of the fluorescence res­
ponse of PLP standards between 4 and 400 nmol/L was established. For routine 
purposes a working standard of approximately 50 nmol/L PLP was processed after 
each fourth or fifth whole blood sample being processed in duplicate. 
The minimum detectable concentration was 2 nmol/L at a fluorescence response of 
signal-to-noise ratio of at least three. The intraassay and interassay coefficients of 
variation as calculated from a whole blood control stored at -20°C until use were 
1.6% (20 replicate determinations, mean concentration 52 nmol/L) and 5.5% (15 
determinations on several days, mean concentration 53 nmol/L), respectively. 
Cystathionine ß-synthase (CBS, EC 4.2.1.22) 
Skin fibroblasts were obtained by a pinch biopsy from the arm. The fibroblasts were 
grown just to confluency in Eagle's minimal essential medium supplemented with 1% 
nonessential amino acids, 10% fetal calf serum and antibiotics (Grand Island Biologi-
cal Co., Grand Island, NY). Cells were washed with phosphate-buffered saline (PBS, 
pH 7.4), harvested by using trypsin solution (0.25% w/v), washed three times with 
cold PBS and the cell pellet was stored at -80°C until analysis. 
CBS catalyzes the reaction of homocysteine to cystathionine (Figure 3.1). CBS 
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activity was measured according to Fowler et al. (1978) with some minor modifica­
tions [Boers et al., 1985a]. In short, the cell pellet was suspended in 250 μ ι 50 mM 
potassium phosphate and 0.1% Lubrol, pH 7.4, 30 minutes at 0°C. After 10 minutes 
centrifugaron at 1000 χ g, the supernatant was used for the assay. The assay mixtu­
re contained: 0.1 mol/L Tris/HCI, 8 mmol/l serine, 0.1 MBq L-[U-,4C]serine (6.3 
MBq/mol), 15 mmol/L homocysteine, 1 mmol/L PLP, and 50 μ ι fibroblasts superna­
tant; total volume 100 μΙ, pH 8.6. After 5 minutes preincubation at 37°C, the incuba­
tion was started by addition of L-homocysteine. After 4 hours incubation at 37°C, a 15 
μ ι aliquot of the assay mixture was applied to Whatman 3 mm chromatography 
paper, 46 χ 2.5 cm. Separation of [14C]serine from [4 (^cystathionine was achieved 
by descending chromatography in isopropanol:H20:formic acid, 80:20:6, for 40 hours. 
The position corresponding to cystathionine was cut into strips and their radioactivi­
ties were measured. Protein was measured according to Lowry et al. (1951). The 
same procedure was repeated using an assay mixture without addition of PLP. The 
activity of CBS is expressed as nmol cystathionine/mg protein.h. 
5,1O-Methylenetetrahydrofolate reductase (MTHFR, EC 1.1.1.68) 
Lymphocytes were isolated from 20 mL heparinized blood using Lymphoprep (Nyco-
med Pharma AS, Oslo, Norway) [Jondal et al., 1972] and were washed twice with 
Hank's buffer (ICN Biomedicals INC, Costa Mesa, UK). The cell pellet was stored at 
-80°C until enzyme assay. 
MTHFR catalyzes the reaction of 5,10-methylenetetrahydrofolate to 5-methyltetrahy-
drofolate (Figure 3.1). MTHFR activity was determined radiochemically in lymphocy­
tes, in its physiological reverse direction [Engbersen et al., 1995]. 5-[Methyl-14C]me-
thyltetrahydrofolate (1.9 MBq/mol, barium salt; Amersham International pic, Amers-
ham, UK) served as the substrate in the presence of menadione as electron accep­
tor. Activities were measured by a modification of the method of Kang et al. (1991). 
The cells were resuspended in 50 mmol/L potassium phosphate buffer, pH 7.2, 
frozen and thawed three times, and centrifuged for 40 minutes at 15,800 χ g. A part 
of the supernatant was preincubated for 5 minutes at 46°C to determine the heat 
stability of the enzyme (Eppendorf 5436 thermomixer, Hamburg, Germany). Diso-
dium salt (FAD) was omitted during this heat inactivation [Rosenblatt and Erbe, 
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1977]. The incubation mixture, with a final volume of 600 μι , consisted of 0.18 mol/l 
potassium phosphate buffer (pH 6.8), 1.15 mmol/L EDTA (pH 7.0), 11.5 mmol/L 
ascorbic acid, 54 μπιοΙ/ί FAD, 20 μιτιοΙ/Ι. 5-[Methyl-uC]methyltetrahydrofolate 
(500,000 dpm), 3.5 mmol/L menadione and a maximum of 250 μ ι enzyme extract 
(preincubated supernatant or normal supernatant). The incubation was started by 
addition of menadione and lasted for 20 minutes in the dark at 37°C. The blank 
contained all the components of the incubation mixture, except enzyme extract. The 
incubation was terminated by the addition of 10 μ ι of 1.0 mmol/L carrier formaldehy­
de, 50 μσιοΐββ dimedone in 200 μ ι ethanol:water (1:1) and 100 μ ι 3.0 mol/L potas­
sium acetate, pH 4.5. The reaction mixture was heated at 95°C for 15 minutes, after 
which it was cooled on ice for about 10 minutes. The reaction mixture was added to 
3.0 mL toluene and stirred vigorously for 15 seconds. After low speed centrifugation, 
2.0 mL of the toluene phase was taken for the measurement of radioactivity. Protein 
was determined by the method of Lowry et al. (1951). MTHFR activity is expressed 
as nmoles formaldehyde/mg protein.h. 
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HOMOCYSTEINE STATUS 
OF PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN 
WITH NORMAL PREGNANCY OUTCOME 
ABSTRACT 
Objective To compare the concentrations of plasma homocysteine in premenopausal 
and postmenopausal women with normal pregnancy outcome, and to examine a 
possible relationship between the homocysteine and estrogen status 
Design Forty-six premenopausal and 26 postmenopausal healthy women without a 
history of vascular disease or adverse pregnancy outcome were recruited by public 
advertisement The homocysteine status was studied by standardized oral methioni-
ne loading test, and the estrogen status was assessed by the measurement of serum 
17ß-estradiol 
Results Median fasting and postmethionine plasma homocysteine concentrations 
were significantly higher in postmenopausal women as compared to premenopausal 
women In premenopausal women, postmethionine plasma homocysteine was 
negatively and significantly correlated to serum 17ß-estradiol 
Conclusions Plasma homocysteine concentrations, both fasting and after methionine 
loading, are significantly higher in postmenopausal women than in premenopausal 
women In premenopausal women, the higher concentrations of serum 17ß-estradiol 
may account in part for the lower concentrations of postmethionine plasma homocys-
teine 
Wouters MGAJ Moorrees MThEC, Van der Mooren MJ, Blom HJ, Boers GHJ, Schellekens LA, 
Thomas CMG, Eskes TKAB Plasma homocysteine and menopausal status Eur J Clin Invest 1995, 
25 801-5 
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INTRODUCTION 
The serum concentrations of homocysteine-cysteine mixed disulfide and homocys-
tine were demonstrated to be significantly lower in premenopausal than in postmeno-
pausal women [Boers et al., 1983; Brattström et al., 1985]. It was proposed that a 
uniquely efficient methionine metabolism may account for the lower incidence of 
vascular disease in women before menopause [Boers et al., 1983]. By contrast, it 
was recently reported that the plasma concentrations of free and total homocysteine 
are independent of menopausal status [Andersson et al., 1992a]. 
OBJECTIVE 
To compare the concentrations of plasma homocysteine in premenopausal and post-
menopausal women with normal pregnancy outcome, and to examine a possible 
relationship between the homocysteine and estrogen status. 
DESIGN 
Forty-six premenopausal and 26 postmenopausal healthy women without a history of 
vascular disease or adverse pregnancy outcome were recruited by public advertise-
ment. The selection criteria are listed in Table 4.1. The characteristics of both groups 
are summarized in Table 5.1. The homocysteine status was studied by standardized 
oral methionine loading test (Chapter 4), and the estrogen status was assessed by 
the measurement of serum 17ß-estradiol [Thomas et al., 1977]. 
Table 5.1. Characteristics of premenopausal and postmenopausal women* 
Age (y) 
Body weight (kg) 
Number of pregnancies 
Number of miscarriages 
Premenopausal 
N = 46 
36(27-44) 
60 (43 - 80) 
2 (1 -4 ) 
ot 
women Postmenopausal women 
N = 26 
54 (50 - 60) 
66 (49 - 90) 
3 (1 -4 ) 
ot 
* Values represent medians (minimum - maximum); f As defined by selection criteria (Table 4.1). 
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STATISTICAL ANALYSIS 
Wilcoxon rank sum test was used to analyze the quantitative differences between the 
two groups studied. Spearman's rank correlation was used to measure the associa­
tions between variables. P-values were two-tailed, and Ρ < 0.05 was considered 
statistically significant. 
RESULTS 
The median concentrations of plasma homocysteine, both fasting and after methioni­
ne loading, were significantly higher in postmenopausal women as compared to 
premenopausal women (Table 5.2). Figure 5.1 depicts the individual fasting and 
postmethionine plasma homocysteine concentrations of both groups studied. 
Due to the selection criterion, the median concentration of serum 17ß-estradiol was 
significantly higher in premenopausal than in postmenopausal women (Table 5.2). In 
two postmenopausal women, serum 17ß-estradiol concentrations were below the 
detection limit of 38 pmol/L. 
The blood vitamin concentrations are listed in Table 5.2. Median serum and red cell 
concentrations of folate were higher in postmenopausal women than in premenopau-
sal women, but the difference was only significant in case of serum folate Median 
serum vitamin B12 was significantly lower in postmenopausal women as compared to 
Table 5.2. Concentrations of plasma homocysteine, fasting and after methionine loading, serum 
17ß-estrudiol, and blood vitamins in premenopausal and postmenopausal women' 
Plasma fasting homocysteine (pmol/L) 
Plasma postmethionine homocysteine (pmolL) 
Serum 17u-estradiol (pmol/L) 
Serum folate (nmol/L) 
Red cell folate (nmol/L) 
Serum vitamin B12 (pmol/L) 
Whole blood PLP (nmol/L) 
Premenopausal Postmenopausal P-value of 
women vromen difference 
N = 46 N = 26 t 
9(6-19) 11(7-23) <0.05 
29 (20 - 55) 41 (28 - 95) < 0 05 
715 (330 - 1500) 73 (47 - 150)t < 0 05 
14(7-25) 16(7-27) < 0 05 
500 (310 - 1000) 565 (280 - 850) 0 08 
270(100-580) 210(64-400) < 0 05 
53(27-160) 45(28-66) 0 08 
 (  -19) 
 (  - ) 
( -1500) 
( -1000) 
 (  -1  
* Values represent medians (minimum - maximum), fN = 24,t Wilcoxon rank sum test 
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premenopausal women. The median concentrations of whole blood pyridoxal-5'-
phosphate (PLP, an active form of vitamin B6) were not significantly different 
between groups. 
100 
Plasma homocysteine 
|pmol/L] 
80 
60 
40 
20 
i 
Ï 
χ 
x 
Figure 5.1. 
Premenopausal Postmenopausal 
Individual concentrations of plasma homocysteine, fasting (X) and after methionine 
loading (A), in premenopausal (N = 46) and postmenopausal women (N = 26). 
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Table 5.3 lists the Spearman's rank correlation coefficients between plasma homo-
cysteine, fasting as well as after methionine loading, and serum 17ß-estradiol, age, 
body weight, and blood vitamins in premenopausal and postmenopausal women. In 
premenopausal women, postmethionine plasma homocysteine, unlike fasting plasma 
homocysteine, was negatively and significantly correlated to serum 17ß-estradiol 
(Figure 5.2). In postmenopausal women, no significant correlations between plasma 
homocysteine and estrogen status were found. Neither in premenopausal nor in 
postmenopausal women were fasting and postmethionine plasma homocysteine 
significantly correlated to age or body weight. In premenopausal women, fasting and 
postmethionine plasma homocysteine were negatively and significantly correlated to 
serum folate, but not to the other vitamins. In postmenopausal women, fasting 
plasma homocysteine was negatively and significantly correlated to the vitamins 
studied, except for PLP, whereas postmethionine plasma homocysteine was 
negatively and significantly correlated to serum folate, but not to the other vitamins. 
Table 5.3. Correlations between plasma homocysteine, fasting and alter methionine loading, and 
serum 17ß-estradiol, age, body weight, and blood vitamins in premenopausal and 
postmenopausal women* 
Premenopausal women 
N = 46 
Postmenopausal women 
N = 26 
Serum 17ß-estradiol 
Age 
Body weight 
Serum folate 
Red cell folate 
Serum vitamin B12 
Whole blood PLP 
Fasting 
plasma 
homocysteine 
-0.06 
+ 0.11 
-0.15 
- 0.43* 
+ 0.07 
+ 0.08 
+ 0.03 
Postmethionine 
plasma 
homocysteine 
- 0.34t 
-0.05 
+ 0.07 
- 0.48+. 
+ 0.11 
+ 0.07 
+ 0.04 
Fasting 
plasma 
homocysteine 
+ 0.24+ 
+ 0.07 
+ 0.01 
- 0.78+. 
- 0.49+. 
- 0.50+. 
-0.08 
Postmethionine 
plasma 
homocysteine 
+ 0.28 
+ 0.10 
+ 0.08 
- 0.39+. 
-0.37 
-0.08 
+ 0.03 
' Values are Spearman's rank correlation coefficients;+ N = 24; + Significant correlation, Ρ < 0.05 
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Postmethionine plasma homocysteine [μπΊθΙ/L] 
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Figure 5.2. Scatter diagram of postmethionine plasma homocysteine and serum 17ß-estradiol in 
premenopausal (f r = - 0.34, Ρ < 0.05) and postmenopausal women (' г - + 0.28, P = 
0.18). 
DISCUSSION 
Plasma homocysteine, serum 17ß-estradiol, and blood vitamin concentrations were 
studied in 46 healthy premenopausal and 26 healthy postmenopausal women. Our 
results clearly demonstrate that median plasma homocysteine concentrations, both 
fasting and after methionine loading, are higher in postmenopausal women as 
compared to premenopausal women (Table 5.2). The results of our study confirm 
those of other reports which measured homocysteine either as free disulfides, before 
as well as after methionine loading [Boers et al., 1983; Brattström et al., 1985], or as 
protein-bound homocysteine in the fasting state [Kang et al., 1986a]. By contrast, 
Andersson et al. (1992a) did not find significant differences in plasma total homocys-
teine concentrations, either fasting or after methionine loading, relating to menopau-
sal status. As yet, we have no reasonable explanation for this discrepancy, although 
some differences in subject selection and laboratory methods may be of importance. 
Several studies have demonstrated a significantly positive correlation of age with 
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plasma homocysteine in healthy women [Boers et al., 1983; Kang et al., 1966a; 
Malinow et al., 1990; Mölgaard et al., 1992; Fermo et al., 1993; Selhub et al., 1993; 
Brattström et al., 1994]. Our results also suggest an age-dependent increase of 
plasma homocysteine. Neither in premenopausal nor in postmenopausal women, 
however, was plasma homocysteine significantly correlated to age, possibly due to 
the narrow ranges of age (27 - 44 and 50 - 60 years, respectively). Interestingly, 
Kang et al. (1986a) have reported an abrupt increase of plasma homocysteine 
among women after 50 years of age, suggesting a negative relationship with 
hormonal changes after menopause. Our study is probably the first to report a 
significantly negative correlation between the concentrations of postmethionine 
plasma homocysteine and serum 17ß-estradiol in premenopausal women, unlike 
postmenopausal women (Table 5.3, Figure 5.2). We speculate that in premenopausal 
women, the higher concentrations of serum 17ß-estradiol enhance the transsuda-
tion and/or remethylation of elevated plasma homocysteine after methionine loading. 
This hypothesis is in line with the observed reduction of blood homocysteine in 
women during pregnancy, a condition which is characterized by a high concentration 
of circulating estrogens [Kang et al., 1986b; Andersson et al., 1992b]. Additionally, 
we have recently reported that high fasting serum homocysteine concentrations may 
decrease by natural estrogen supplementation after menopause [Van der Mooren et 
al., 1994]. Synthetic estrogens, like ethinyl-estradiol in oral contraceptives, may affect 
homocysteine metabolism as well, although data are conflicting [Brattström et al., 
1992a; Steegers-Theunissen et al., 1992b]. 
Serum folate and serum vitamin B12 are important determinants of fasting plasma 
homocysteine in healthy subjects [Andersson et al., 1992a; Brattström et al., 1994; 
Jacobson et al., 1994], and in patients with vascular disease [Brattström et al., 1990; 
Pancharuniti et al., 1994]. This is confirmed by the present results, except that in 
premenopausal women, the concentrations of fasting plasma homocysteine were not 
correlated to those of serum vitamin B12 (Table 5.3). In postmenopausal women, 
unlike premenopausal women, fasting plasma homocysteine concentrations were 
negatively and significantly correlated to red cell folate concentrations (Table 5.3). 
Altogether, this data suggests that fasting plasma homocysteine is more dependent 
on blood vitamins in postmenopausal women as compared to premenopausal 
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women. In a recent study of an elderly population, aged 67-96 years, it appeared 
that a marginal or manifest vitamin deficiency contributed to two-third of the cases of 
high plasma homocysteine [Selhub et al., 1993]. 
In the present study, postmethionine plasma homocysteine was negatively and 
significantly correlated to serum folate, both in premenopausal and postmenopausal 
women. By contrast, the increase of plasma homocysteine after methionine loading 
and serum folate were reported to be not significantly correlated [Brattstròm et al., 
1990; Andersson et al., 1992a]. 
The risk of cardiovascular disease in women increases rapidly after menopause. 
Higher concentrations of plasma homocysteine are associated with a higher risk of 
cardiovascular disease [Stampfer et al., 1992]. Our data support the hypothesis that 
in women after menopause the higher concentrations of plasma homocysteine 
contribute to the higher risk of cardiovascular disease. 
It is concluded that plasma homocysteine concentrations, both fasting and after 
methionine loading, are significantly higher in postmenopausal women than in 
premenopausal women. In premenopausal women, the higher concentrations of 
serum 17ß-estradiol may account in part for the lower concentrations of post-
methionine plasma homocysteine. 
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HOMOCYSTEINE AND VITAMIN STATUS 
OF WOMEN WITH RECURRENT MISCARRIAGE 
ABSTRACT 
Objectives. To establish the prevalence of hyperhomocystememia in women with 
recurrent miscarriage, and to examine the association between the homocysteine 
and vitamin status in these women 
Design Forty-six women with normal pregnancy outcome (controls) and 180 women 
with recurrent miscarriage (study group) were selected The homocysteine status 
was studied by standardized oral methionine loading test Hyperhomocystememia 
was defined as a fasting and/or postmethionine plasma homocysteine concentration 
above the estimated 97 5 percentile level of the controls The vitamin status was 
investigated by the measurement of serum and red cell folate, serum vitamin B12, 
and whole blood pyndoxal-5'-phosphate (PLP, an active form of vitamin B6) in a 
fasting state 
Results Hyperhomocystememia was diagnosed in 4 controls (9%) and 39 women of 
the study group (22%, Ρ < 0 05) In women with recurrent miscarriage, plasma 
homocysteine concentrations were significantly and negatively correlated to blood 
concentrations of folate and vitamin B12, but not to PLP 
Conclusions. Hyperhomocystememia is associated with recurrent miscarriage In 
women with recuaent miscarriage, folate and vitamin B12 are important determinants 
of the homocysteine status 
Wouters MGAJ, Boers GHJ, Blom HJ, Tnjbels JMF, Thomas CMG, Borm GF, Steegers-Theunissen 
RPM, Eskes TKAB Hyperhomocystememia A risk factor for women with unexplained recurrent early 
pregnancy loss Fértil Stenl 1993,60 820-5 
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INTRODUCTION 
A recent preliminary study has suggested a relationship between recurrent spontane-
ous abortion and hyperhomocysteinemia [Steegers-Theunissen et al., 1992a]. The 
present study reports the results of our investigation in an extended group of women 
with recurrent miscarriage. 
OBJECTIVE 
To establish the prevalence of hyperhomocysteinemia in women with recurrent 
miscarriage, and to examine the association between the homocysteine and vitamin 
status in these women. 
DESIGN 
Forty-six premenopausal women with normal pregnancy outcome (control group) and 
180 women with recurrent miscarriage (study group) were included. The selection 
criteria are listed in Table 4.1. Some characteristics of the control and study group 
are summarized in Table 6.1. Seventy percent (n = 126) of women of the study group 
had suffered from three consecutive miscarriages or more. About one-third (n = 68) 
of women had experienced recurrent miscarriage next to one or more pregnancies 
that had developed beyond 16 weeks of amenorrhea. Overall, all the women of the 
study group had had 637 spontaneous abortions. Fifty-eight percent (n = 368) of 
these pregnancy losses were histologically confirmed. In the remaining 42% (n = 
269), early pregnancy was diagnosed by a positive routine urinary human chorionic 
gonadotropin (hCG) test and/or ultrasound imaging of at least one intra-uterine 
gestational sac, with or without positive heart-beat. Ninety percent (n = 571) of all 
miscarriages ended before 12 weeks of menstrual age. 
The homocysteine status was studied by standardized oral methionine loading test 
(Chapter 4). Hyperhomocysteinemia was defined as a fasting and/or postmethionine 
plasma homocysteine concentration above the estimated 97.5 percentile level of the 
controls. The vitamin status was investigated by the measurement of fasting concen-
trations of serum and red cell folate, serum vitamin B12, and whole blood pyridoxal-
5'-phosphate (PLP, an active form of vitamin B6). 
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Table 6.1. Characteristics of the control and study group* 
Age (y) 
Body weight (kg) 
Number of pregnancies 
Pregnancy outcome 
Miscarriage 
Induced abortion 
Ectopic pregnancy 
Fetal death 
Live birth 
Control group 
N = 46 
36 (27 - 44) 
60 (43 - 60) 
2 ( 1 - 4 ) 
ot 
0 ( 0 - 1 ) 
ot 
ot 
2 ( 1 - 4 ) 
Study group 
N = 180 
32 (22 - 47) 
64(45-117) 
4 (2 -14) 
3 ( 2 - 1 0 ) 
0 ( 0 - 1 ) 
0 (0 - 2) 
0 ( 0 - 2 ) 
0 (0 - 3) 
* Values represent medians (minimum - maximum); f As defined by selection criteria (Table 4.1). 
STATISTICAL ANALYSIS 
In controls, the 2.5- and 97.5 percentile levels of plasma homocysteine and blood 
vitamins were calculated as means ±1.96 standard deviations (SDs) after log 
transformation. In women of the study group, true 2.5- and 97.5 percentile values 
were established. Wilcoxon rank sum test was used to analyze the quantitative 
differences, and uncorrected chi square test to analyze the proportional differences 
between the two groups studied. Spearman's rank correlation was used to measure 
the associations between variables. P-values were two-tailed, and Ρ < 0.05 was 
considered statistically significant. 
RESULTS 
Figure 6.1 depicts the individual concentrations of fasting and postmethionine plasma 
homocysteine in the control and study group, respectively. In the control group, 
fasting plasma homocysteine concentrations ranged from 6 to 19 pmol/L, and 
postmethionine plasma homocysteine concentrations from 20 to 55 μπηοΙ/L. The 97.5 
percentile levels of fasting and postmethionine plasma homocysteine in controls were 
calculated as 15 and 51 pmol/L, respectively. In the study group, fasting plasma 
homocysteine concentrations varied from 3 to 81 μπηοΙ/L, and postmethionine plasma 
homocysteine concentrations from 19 to 116 pmol/L. 
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Figure 6.1. Individual concentrations of fasting and postmethionine plasma homocysteine in 
women of the control (n = 46, upper part) and study group (n = 180, lower part). The 
dotted horizontal and vertical lines represent the 97.5 percentile control levels of 
fasting and postmethionine plasma homocysteine, 15 and 51 umol/L, respectively. 
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Table 6.2. Prevalence of hyperhomocystememia in women of the control and study group as 
related to the level of fasting and postmethionine plasma homocysteine'' 
Fasting plasma Postmethionine plasma Control group Study group 
homocysteine homocysteine N = 46 N = 180 
Normal Normal 42 (91%) 141 (78%) 
High Normal 3(7%) 10(6%) 
Normal High 1 (2%) 17 (9%) 
High High 0(0%) 12(7%) 
* Values represent numbers (proportions) 
Hyperhomocystememia, ι e fasting plasma homocysteine above 15 pmol/L and/or 
postmethionine plasma homocysteine above 51 μπηοΙ/Ι-, was present in 4 of 46 (9%) 
controls and 39 of 180 (22%) women of the study group (Table 6 2, uncorrected chi 
square, 4 0, Ρ < 0 05) 
The median concentrations of plasma homocysteine and blood vitamins are presen­
ted in Table 6 3 Median fasting and postmethionine plasma homocysteine were sig­
nificantly higher in the study group as compared to the control group The median 
concentrations of the vitamins studied were not significantly different, except for PLP 
the median of which was significantly lower in women of the study group as compa­
red to the controls 
Table 6.3. Concentrations of plasma homocysteine and blood vitamins in women of the control 
and the study group* 
Fasting plasma homocysteine (pmol/L) 
Postmethionine plasma homocysteine (pmol/L) 
Serum folate (nmol/L) 
Red cell folate (nmol/L) 
Serum vitamin B12 (pmol/L) 
Whole blood PLP (nmol/L) 
Control group Study group P-value of 
N = 46 N = 180 difference 
t 
9(6-15) 11(6-26) <005 
29(18-51) 37(20-75) < 0 05 
14(7-25) 13(5-28) 0 26 
500 (300 - 818) 500 (230-1500) 0 87 
270 (125 - 562) 245 (73 - 490) 0 21 
53(28-90) 45 (26 - 72) < 0 05 
* Values represent medians (2 5-97 5 percentile levels), t Wilcoxon rank sum test 
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In the control as well as the study group, fasting and postmethionme plasma homo­
cysteine were significantly and positively correlated (r = + 0 66 and г = + 0 68, 
respectively, Figure 6 1) In the study group, neither fasting nor postmethionme 
plasma homocysteine were significantly correlated to the number of spontaneous 
abortions (r = - 0 11, Ρ = 0 15, and r = -011,P = 014, respectively) Table64 lists 
the associations between plasma homocysteine and blood vitamins in women of the 
control and study group 
Figures 6 2 to 6 5 are scatter diagrams of the concentrations of blood vitamins and 
plasma homocysteine in women of the study group Almost one-fifth (n = 32) of 
women with recurrent miscarriage had either one or more subnormal blood vitamin 
concentrations, ι e below the 2 5 percentile levels of controls The great majority (n = 
28) was folate and/or vitamin B12 deficient Seventeen of all vitamin deficient women 
of the study group (53%) were hyperhomocysteinemic 
DISCUSSION 
The main finding of the present study is the observation of hyperhomocystememia in 
about one-fifth of women with recurrent miscamage This result confirms a previous 
preliminary report [Steegers-Theunissen et al, 1992a] 
Table 6.4. Associations between plasma homocysteine and blood vitamins in women of the 
control and study group' 
Control group 
N = 4 6 
Fasting plasma 
homocysteine 
Postmethionme 
plasma 
homocysteine 
Study group 
N = 1 8 0 
Fasting plasma 
homocysteine 
Postmethionme 
plasma 
homocysteine 
Serum folate - 0 43t - 0 48+ - 0 45t - 0 41+ 
Red cell folate + 0 0 7 + 0 1 1 - 0 5 0 + -033+ 
Serum vitamin B12 + 0 08 + 0 07 - 0 46+ - 0 27+ 
Whole blood PLP + 0 03 + 0 04 - 0 11 - 0 08 
* Values represent Spearman's rank correlation coefficients, t Statistically significant (P<0 05) 
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Figure 6.2. 
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Postmethionine plasma homocysteine [μιτιοΙ/L] 
Scatter diagrams of the concentrations of plasma homocysteine, fasting and after 
methionine loading, and serum folate in women of the study group. The dotted lines 
represent the 2.5 and 97.5 percentile levels of the control group (see Table 6.3). 
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Figure 6.3. Scatter diagrams of the concentrations of plasma homocysteine, fasting and after 
methionine loading, and red cell folate in women of the study group The dotted lines 
represent the 2 5 and 97 5 percentile levels of the control group (see Table 6 3) 
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Scatter diagrams of the concentrations of plasma homocysteine, fasting and after 
methionine loading, and serum vitamin B12 in women of the study group. The dotted 
lines represent the 2.5 and 97.5 percentile levels of the control group (see Table 6.3). 
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Figure 6.5. Scatter diagrams of the concentrations of plasma homocysteine, fasting and after 
methionine loading, and whole blood PLP in women of the study group. The dotted 
lines represent the 2.5 and 97.5 percentile levels of the control group (see Table 6.3). 
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The question arises how elevated concentrations of plasma homocysteine may 
cause early pregnancy loss. There is convincing evidence that even a mild elevation 
of blood homocysteine concentrations is leading to premature vascular disease 
[Kang et al., 1992; Ueland et al., 1992]. Theoretically, homocysteine may act as an 
atherogenic and thrombotic agent in decidual and chorionic vessels, leading to 
disturbed implantation of the conceptus. Microthrombosis, vasospastic changes, 
fibrin depositions, and necrosis are common morphologic features in tissue speci-
mens from spontaneous abortion [Rushton, 1988]. A second mechanism by which 
abnormally high homocysteine levels may disturb normal pregnancy outcome is 
embryotoxicity. Recently, a high concentration of L-homocysteine (4 mM) was de-
monstrated to be toxic to rat embryos in vitro. In lower concentrations (1 or 2 mM), 
the addition of L-homocysteine was not toxic and promoted normal development of 
the rat embryos in serum that without supplementation caused neural tube defects 
(NTDs) in the embryos. Interestingly, L-methionine had the same beneficial effect at 
even lower concentrations, and the embryotoxic effect of L-homocysteine was 
attenuated by the addition of L-methionine [Van Aerts et al., 1994]. Methionine is the 
precursor of S-adenosylmethionine, which is the universal methyl group donor in 
transmethylation reactions essential to normal embryonic growth and development. 
As a low ratio of S-adenosylmethionine and S-adenosylhomocysteine will inhibit 
many transmethylation reactions [Cantoni et al., 1978], it is hypothesized that 
increased S-adenosylhomocysteine formation resulting from high concentrations of 
homocysteine is the first step in the embryotoxic mechanism of L-homocysteine [Van 
Aerts et al., 1994]. In this respect, it is interesting that NTDs are the most common 
group of malformations identified in tissue specimens from spontaneous abortion 
[Creasy and Alberman, 1976], and that the development of NTD in the offspring has 
been associated with hyperhomocysteinemia in the mother [Steegers-Theunissen et 
al., 1990a; 1994]. 
Hyperhomocysteinemia may result from disorders in the transsulfuration or remethy-
lation of homocysteine [Mudd et al., 1989]. Enzymatic defects as well as vitamin 
deficiencies may interfere with both routes. The activities of cystathionine ß-synthase 
and 5,10-methylenetetrahydrofolate reductase were measured in a subgroup of 
hyperhomocysteinemic women with recurrent miscarriage. The results are presented 
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in Chapter 7. In the following, the possible role of vitamins will be discussed. 
PLP is a cofactor in the transsudation of homocysteine. In the present study, the 
median PLP concentration was significantly lower in women of the study group as 
compared to the controls (Table 6.3). Subnormal PLP concentrations were found in 
four hyperhomocysteinemic women with recurrent miscarriage, three of whom with 
high postmethionine plasma homocysteine (Figure 6.5). A defect of homocysteine 
transsulfuration due to PLP deficiency may be present in a small number of the 
women with hyperhomocysteinemia. 
Folate and vitamin B12 are involved in the remethylation of homocysteine [Rosen-
blatt, 1989; Fenton and Rosenberg, 1989]. Therefore, malnutrition and malabsorption 
of folate and vitamin B12 may lead to hyperhomocysteinemia. Hibbard (1964) has 
already suggested a higher prevalence of defective folate metabolism in women with 
two or more consecutive abortions compared to controls, as indicated by their 
excessive formimino-glutamic acid excretion after histidine loading. Low serum folate 
and/or cobalamin concentrations have been reported in 30% of women with recurrent 
spontaneous abortion [Pietrzik et al., 1992]. In the present study, however, we have 
observed no significant differences between the median blood concentrations of 
folate and vitamin B12 in women with recurrent miscarriage and normal pregnancy 
outcome (Table 6.3). Nevertheless, subnormal concentrations of folate and vitamin 
B12 were detected in a substantial proportion of women of the study group (n = 28. 
16%; Figures 6.2 to 6.4), and in only one control subject. Accordingly, the concentra-
tions of folate and vitamin B12 were significantly and negatively correlated to those of 
plasma homocysteine (Table 6.4). We do not rule out the possibility that spontaneous 
abortion, at least in some cases, results from a primary nutritional deficit of vitamin 
B12 and/or folate, of which hyperhomocysteinemia is merely a concomitant finding. 
Apart from maternal hyperhomocysteinemia, inherited disorders of homocysteine 
metabolism of the conceptus itself may contribute to its death. Studies in trophoblast 
cells of tissue specimens from spontaneous abortion should provide data on this 
option. 
Pyridoxine and/or folic acid administration have been reported to reduce plasma 
homocysteine concentrations in vascular patients with hyperhomocysteinemia 
[Brattstròm et al., 1990; Dudman et al., 1993; Franken et al., 1994; Van den Berg et 
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al., 1994]. According to our experience in nonpregnant hyperhomocysteinemic 
women, normohomocysteinemia may well be achieved by daily oral administration of 
only folic acid in a dose as low as 1 mg (Chapter 8). The question remains whether 
biochemical normalization of hyperhomocysteinemia by periconceptional folate 
administration will favor pregnancy outcome in women with unexplained recurrent 
miscarriage (Chapter 9). A randomized controlled prevention trial should provide the 
answer to this important question. 
In conclusion, hyperhomocysteinemia is associated with recurrent miscarriage. In 
women with recurrent miscarriage, folate and vitamin B12 are important determinants 
of the homocysteine status. 
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CYSTATHIONINE ß-SYNTHASE ACTIVITY 
AND THERMOLABILE 5,10-METHYLENETETRAHYDROFOLATE 
REDUCTASE IN HYPERHOMOCYSTEINEMIC WOMEN 
WITH RECURRENT MISCARRIAGE 
ABSTRACT 
Objective. To estimate the prevalence of reduced cystathionine ß-synthase (CBS) 
activity and thermolabile 5,10-methylenetetrahydrofolate reductase (MTHFR) in 
hyperhomocysteinemic women with recurrent miscarriage. 
Design. CBS activities were measured in cultured fibroblasts of 12 control subjects, 
13 obligate heterozygotes for CBS deficiency, i.e. parents or children of patients 
suffering from homocystinuria due to homozygosity for CBS deficiency, and 7 hyper-
homocysteinemic women with recurrent miscarriage. Specific and residual MTHFR 
activities were measured in isolated lymphocytes of 23 control subjects, and 17 
hyperhomocysteinemic women with recurrent miscarriage. Thermolabile MTHFR was 
defined as a residual activity after heat inactivation of less than the lowest control 
value. 
Results. CBS activity within the range of obligate heterozygotes and thermolabile 
MTHFR were observed in one out of seven and three out of 17 hyperhomocysteine-
mic women with recurrent miscarriage, respectively. 
Conclusions. Reduced CBS activity and thermolabile MTHFR were observed in a 
minor fraction of hyperhomocysteinemic women with recurrent miscarriage. Molecu-
lar genetic studies may be more appropiate in exploring these enzymic defects as a 
potential cause for hyperhomocysteinemia. 
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INTRODUCTION 
Hyperhomocysteinemia may result from enzymic disorders in homocysteine trans-
sulfuration and/or remethylation (Figure 3.1) [Mudd et al., 1989]. A decreased activity 
of cystathionine ß-synthase (CBS) has been reported in the majority of hyperhomo-
cysteinemic patients with vascular disease [Boers et al., 1985; Clarke et al., 1991]. 
Thermolabile 5,10 methylenetetrahydrofolate reductase (MTHFR) has been recently 
demonstrated in 11 out of 39 hyperhomocysteinemic vascular patients [Engbersen et 
al., 1995]. In the present study, CBS and MTHFR activities were measured in hyper-
homocysteinemic women with recurrent miscarriage. 
OBJECTIVE 
To estimate the prevalence of reduced CBS activity and thermolabile MTHFR in 
hyperhomocysteinemic women with recurrent miscarriage. 
DESIGN 
CBS activities (without addition of pyridoxal-5'-phosphate, PLP) were measured in 
cultured fibroblasts of 12 control subjects, 13 obligate heterozygotes for CBS defi-
ciency, i.e. parents or children of patients suffering from homocystinuria due to 
homozygosity for CBS deficiency, and 7 hyperhomocysteinemic women with recur-
rent miscarriage. 
Specific and residual MTHFR activities were measured in isolated lymphocytes of 23 
control subjects, and 17 hyperhomocysteinemic women with recurrent miscarriage. 
Thermolabile MTHFR was defined as a residual activity after heat inactivation of less 
than the lowest control value [Kang et al., 1988a; 1988b; 1991a]. 
RESULTS 
Table 7.1 summarizes the CBS activities in the three groups studied. The individual 
activities are depicted in Figure 7.1. In one hyperhomocysteinemic woman with 
recurrent miscarriage, CBS activity was within the range of obligate heterozygotes for 
CBS deficiency and outside the normal range (1.7 nmol cystathionine/mg protein.h). 
Data from our laboratory on the specific and residual MTHFR activities of controls 
have been reported elsewhere [Engbersen et al., 1995], and are listed in Table 7.2. 
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Table 7.1. CBS activities (without addition of PLP) in cultured fibroblast of controls, obligate he-
terozygotes, and hyperhomocysteinemic women with recurrent miscarriage* 
Controls 
N = 12 
Obligate 
heterozygotes 
N = 13 
Hyperhomocysteinemic 
women with recurrent 
miscarriage 
N = 7 
CBS activity 
(nmol cystathionme/mg protein h) 
6 2 ( 2 3 - 1 8 2 ) 0 8 ( 0 3 - 2 4 ) 5 9 ( 1 7 - 2 6 0 ) 
' Values are expressed as medians (minimum - maximum) 
20 
10 
Cystathionine ß-synthase activity 
[nmol cystathionine/mg protein h] 
• ! • 
# 
Controls Obligate 
heterozygotes 
Recurrent 
miscarriage 
Figure 7.1. Individual CBS activities (without addition of PLP) in controls (n = 12), obligate hetero-
zygotes (η = 13), and hyperhomocysteinemic women with recurrent miscarriage (n = 
7) The dashed square indicates the hyperhomocysteinemic woman with recurrent 
miscarriage and reduced CBS activity 
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Table 7.2. Specific and residual MTHFR activities in isolated lymphocytes of controls and hyper-
homocysteinemic women with recurrent miscarriage'' 
Controls Hyperhomocysteinemic women with 
recurrent miscarriage 
Thermolabile Thermostable 
N = 22 N = 3 N = 14 
Specific MTHFR activity 
(nmol CH20/mg protein h) 
Residual MTHFR activity 
(% of initial activity) 
15 1 ( 9 1 - 2 6 6 ) 
56 3(35 9 - 7 9 1 ) 
6 7 ( 4 6 - 6 8 ) 
7 4 ( 0 0 - 1 0 2 ) 
21 1(10 8 - 3 1 4 ) 
51 9 (40 7 - 67 6) 
* Values are expressed as medians (minimum - maximum) 
Figure 7 2 is a scatter diagram of the specific and residual MTHFR activities in con­
trols and women of the study group Thermolabile MTHFR was diagnosed in three 
hyperhomocysteinemic women with recurrent miscarriage (18%) There were no 
overlaps between specific and residual MTHFR activities in the thermolabile group 
and those of controls Table 7 2 summarizes the specific and residual activities of 
MTHFR in thermolabile and thermostable women with hyperhomocystememia and 
recurrent miscarriage The median specific MTHFR activity in the thermolabile sub­
group was 44% of the median of controls 
DISCUSSION 
In the present study, CBS activity within the range of obligate heterozygotes for CBS 
deficiency and outside the normal range was observed in only one out of seven 
hyperhomocysteinemic women with recurrent miscarriage Two studies have repor­
ted reduced CBS activity, ι e within the range of obligate heterozygotes, in cultured 
fibroblasts of the majority of hyperhomocysteinemic patients with vascular disease 
[Boers et a l , 1985, Clarke et al ,1991] The consistent identification of patients with 
vascular disease as heterozygotes for CBS deficiency is troubled by the wide range 
of CBS activities found in controls overlapping with the range of those in obligate 
heterozygotes [Boers, 1994] This may be due to the large degree of heterogeneity 
among mutant alleles for CBS [McGill et a l , 1990] 
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Figure 7.2. Specific and residual MTHFR activities in isolated lymphocytes of controls (: η = 22) 
and hyperhomocysteinemic women with recurrent miscarriage (Kn = 17). The dashed 
square contains subjects with thermolabile MTHFR (n = 3). 
A recent molecular study of the CBS coding region in four vascular patients with 
hyperhomocysteinemia and reduced CBS activity did not reveal any mutation previ­
ously identified in heterozygous carriers and homocystinuric patients [Kozich et al., 
1995]. 
Recently, the CBS activities of cultured fibroblasts from 15 vascular patients with 
hyperhomocysteinemia and 31 healthy controls were reported to vary over wide 
ranges and to have a substantial overlap, although the mean CBS activity of patients 
was significantly lower than the mean of controls [Dudman et al., 1993]. In another 
recent study, CBS activities were within the normal range and higher than heterozy­
gote levels in 9 out of 10 hyperhomocysteinemic patients with vascular disease [Eng-
bersen et al., 1995]. The present results are in line with with these observations and 
confirm preliminary data from our laboratory [Steegers-Theunissen et al., 1992a]. 
Overall, it seems that reduced CBS activity is not a main cause of hyperhomocystei­
nemia in women with recurrent miscarriage. 
64 Chapter 7 
Thermolabile MTHFR is another possible cause of hyperhomocysteinemia in vascu-
lar patients. The prevalence of thermolabile MTHFR in 212 coronary artery patients 
has been reported as 17% [Kang et al., 1991]. However, hyperhomocysteinemia was 
not a common finding among patients with thermolabile MTHFR. In a recent study, 
thermolabile MTHFR was established in 11 of 39 hyperhomocysteinemic patients 
with premature vascular disease [Engbersen et al., 1995]. In the present study, 
thermolabile MTHFR was found in a lower proportion of hyperhomocysteinemic 
women with recurrent miscarriage, although numbers are probably too small to draw 
definite conclusions. 
The human gene for MTHFR is localized to chromosome 1. Its cDNA was isolated by 
Goyette et al. (1994). Recently, a common mutation in the MTHFR coding sequence, 
which correlates with reduced activity and increased thermolability of the enzyme in 
lymphocyte extracts, was identified. A significant elevation in plasma homocysteine 
was observed in individuals who were homozygous for this mutation [Frosst et al., 
1995]. Interestingly, a recent study exploring this mutation in NTD affected children 
and their mothers has revealed significantly higher prevalences of homozygosity for 
the mutation as compared to controls. Individuals homozygous for the mutation had 
significantly reduced MTHFR activities, elevated plasma homocysteine, and decrea-
sed plasma folate concentrations. This data suggests that the mutation is a genetic 
risk factor for NTD [Van der Put et al., 1995]. Future studies should explore this 
mutation in women with recurrent miscarriage as well. 
In conclusion, reduced CBS activity and thermolabile MTHFR were observed in a 
minor fraction of hyperhomocysteinemic women with recurrent miscarriage. Molecu-
lar genetic studies may be more appropiate in exploring these enzymic defects as a 
potential cause for hyperhomocysteinemia. 
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EFFECTS OF PYRIDOXIN E AND FOLIC ACID TREATMENT 
ON ELEVATED PLASMA HOMOCYSTEINE CONCENTRATIONS 
IN WOMEN WITH ADVERSE PREGNANCY OUTCOME 
ABSTRACT 
Objective To evaluate the effects of pyndoxine and folic acid treatment on elevated 
plasma homocysteine concentrations in women with adverse pregnancy outcome 
Design Nineteen women with recurrent miscarriage and 18 women with a history of 
placental vasculopathy were selected after hyperhomocystememia was diagnosed by 
oral methionine loading test They were orally treated by either one of three vitamin 
regimens, ι e pyndoxine, 250 mg daily, or folic acid, 1 or 5 mg daily A repeat loading 
test was performed at least four weeks after the start of treatment, and plasma 
homocysteine concentrations were compared 
Results No significant change of the median fasting plasma homocysteine concen­
tration was observed during pyndoxine treatment By contrast, a significant decrease 
of the median fasting plasma homocysteine concentration was noticed during folic 
acid treatment The median reduction of postmethionine plasma homocysteine 
concentrations observed during treatment with folic acid, 5 mg daily, was significantly 
larger as compared to folic acid, 1 mg daily, or pyndoxine 
Conclusions Folic acid seems more effective in reducing elevated plasma homocys­
teine concentrations in women with adverse pregnancy outcome than pyndoxine A 
randomized controlled study would be more appropiate to assess the true homo-
cysteme-lowenng effects of these vitamins 
Wouters MGAJ, Boers GHJ Blom HJ, Hamilton CJCM, Polman MBJ, Steegers-Theunissen RPM, 
Thomas CMG, Eskes TKAB Effects of pyndoxine and folic acid treatment on plasma homocysteine 
concentrations in hyperhomocysteinemic women with adverse pregnancy outcome Submitted 
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INTRODUCTION 
Hyperhomocysteinemia was recently observed to be associated with recurrent mis-
carriage (Chapter 6) [Wouters et al., 1993] and placental vasculopathy, i.e. abruption 
or infarction of the placenta (Chapter 11) [Goddijn-Wessel et al., In press]. 
In patients with vascular disease, pyridoxine and folic acid may reduce elevated 
blood homocysteine concentrations [Brattström et al., 1990; Dudman et al., 1993; 
Franken et al., 1994; Van den Berg et al., 1994]. The effects of pyridoxine and folic 
acid treatment on plasma homocysteine levels in hyperhomocysteinemic women with 
adverse pregnancy outcome, i.e. recurrent miscarriage or placental vasculopathy, are 
yet unknown. 
OBJECTIVE 
To evaluate the effects of pyridoxine and folic acid treatment on elevated plasma 
homocysteine concentrations in women with adverse pregnancy outcome. 
DESIGN 
Nineteen women with recurrent miscarriage and 18 women with a history of placental 
vasculopathy were selected after hyperhomocysteinemia was diagnosed by oral me-
thionine loading test. The characteristics of the women studied are summarized in 
Table 6.1. The present study was not intended as a treatment trial on beforehand, 
but aimed to report the changes in plasma homocysteine levels during intervention in 
a clinical setting. For ethical reasons, all hyperhomocysteinemic women (n = 37) 
were orally treated by either one of three vitamin regimens. In a two-year period, the 
first 11 women who entered the study were treated with pyridoxine, 250 mg daily, the 
following 14 women with folic acid, 5 mg daily, and the last 12 women with folic acid, 
1 mg daily. A repeat test was performed at least four weeks after the start of vitamin 
treatment, and plasma homocysteine concentrations were compared. Additionally, 
eight women who remained hyperhomocysteinemic during single vitamin treatment 
received a combination of pyridoxine, 250 mg daily, and folic acid, 1 or 5 mg daily. 
They underwent a third test at least four weeks after the start of the combined treat-
ment. Subjects did not use additional vitamin supplements or any other medication 
during the study period. No vitamin deficient diets were recorded by questionnaire. 
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Table 8.1. Characteristics of women with adverse pregnancy 
Age (y) 
Body weight (kg) 
Number of pregnancies 
Pregnancy outcome 
Miscarriage 
Induced abortion 
Ectopic pregnancy 
Fetal death 
Live birth 
Recurrent miscarriage 
N = 19 
33(26-47) 
64(55-96) 
4 ( 2 - 9 ) 
3 ( 2 - 6 ) 
0 ( 0 - 1 ) 
0 ( 0 - 1 ) 
0 (0 - 2) 
1 ( 0 - 3 ) 
outcome* 
Placental vasculopathy 
N = 1 8 
29(25-41) 
61 (48 -102) 
2 ( 1 - 4 ) 
0 (0 - 3) 
0 
0 
1 ( 0 - 1 ) 
1 ( 0 - 3 ) 
* Values represent medians (minimum - maximum). 
STATISTICAL ANALYSIS 
Wilcoxon signed-ranks test was used to analyze the concentration differences within 
the treatment groups. Kruskal-Wallis one-way analysis of variance was used to 
analyze the concentration differences and the differences in response to treatment 
between the treatment groups, followed by pairwise Wilcoxon rank-sum tests in case 
of a significant result. Uncorrected chi-square test was used to compare the differen­
ces in normalization rates between the treatment groups. P-values were two-tailed, 
and Ρ < 0.05 was considered statistically significant. 
RESULTS 
Table 8.2 lists age, body weight, pretreatment vitamin status, and period of vitamin 
treatment in the three groups treated with either pyridoxine, 250 mg daily, or folic 
acid, 5 mg daily, or folic acid, 1 mg daily. Renal function (serum creatinine) and liver 
parameters (serum alanine aminotransferase and serum aspartate aminotransferase) 
were not significantly different between the groups studied (data not shown). 
Table 8.3 summarizes the median concentrations of fasting and postmethionine 
plasma homocysteine, as measured before and during treatment with either one of 
the three vitamin regimens. The median response to treatment was calculated from 
plasma homocysteine before [B] and during vitamin treatment [A] as: [A - B] / [B]. 
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Table 8.2. Age, body weight, pretreatment vitamin status, and penod of vitamin treatment in the 
three treatment groups studied" 
Age (y) 
Body weight (kg) 
Pretreatment vitamin status 
Serum folate (nmol/L) 
Red cell folate (nmol/L) 
Serum vitamin B12 (pmol/L) 
Whole blood PLP* (nmol/L) 
Penod of vitamin treatment (wk) 
Pyndoxme 
250 mg daily 
N = 11 
33 (29 - 38) 
63 (52 - 78) 
11(5-23) 
510(250-1000) 
280(140-510) 
42(33-180) 
6(5 -12) 
Folic acid 
5 mg daily 
N = 14 
31(25-47) 
67(54-102) 
9 ( 5 - 1 3 ) 
405 (280 - 600) 
210(100-460) 
37(21-61) 
6 ( 4 - 9 ) 
Folic acid 
1 mg daily 
N = 12 
32 (26 - 37) 
66 (48 -96) 
10(6-20) 
565 (350 - 670) 
240(120-420) 
46 (26 - 66) 
5 ( 5 - 1 2 ) 
P-valuet 
056 
0 42 
0 32 
0 05 
012 
017 
056 
* Values represent medians (minimum - maximum), t Kruskal-Wallis one-way analysis of variance, f 
PyndoxalS'-phosphate (an active form of vitamin B6) 
Prior to treatment, the median concentrations of fasting and postmethionine plasma 
homocysteine were not significantly different between the three groups studied. No 
significant change of the median fasting plasma homocysteine concentration was 
observed during pyndoxine treatment. By contrast, a significant decrease of the 
median fasting plasma homocysteine concentration was noticed during folic acid 
treatment. The median reduction of postmethionine plasma homocysteine concentra­
tions observed during treatment with folic acid, 5 mg daily, was significantly larger as 
compared to folic acid, 1 mg daily, or pyndoxme As a result the normalization rate, 
i.e. the proportion of women that achieved normal concentrations of plasma homo­
cysteine during vitamin treatment, was higher although not significantly different in 
women who received folic acid, 5 mg daily, as compared to women who were treated 
otherwise (uncorrected chi square, 4.4). 
Figure 8 1 depicts the individual changes of the fasting and postmethionine plasma 
homocysteine concentrations in the three treatment groups. In general, higher pre-
treatment concentrations of plasma homocysteine, both before and after methionine 
loading, resulted in larger reductions during vitamin treatment, except for the fasting 
plasma homocysteine concentrations during pyridoxine administration. 
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15(10;35) 
7(6; 11) 
<0.05 
-46 (-78 ; 23) 
16(10;34) 
8 (6:16) 
<0.05 
-47 (-68 ; 7) 
0.05 
<0.05 
<0.05 
Table 9.3. Concentrations of plasma homocysteine before and six hours after orai methionine 
loading, as measured before and during single vitamin treatment in 37 hyperhomocys-
teinemic women with adverse pregnancy outcome* 
Plasma Pyridoxine Folic Acid Folic Acid P-
Homocysteine 250 mg daily 5 mg daily 1 mg daily value 
N = 11 N = 14 N = 12 Ц 
Fasting (pmol/L) 
Before treatment 12 (7; 35) 
During treatment 12 (7 ; 33)** 
P-valuef 0.72 
Response to treatment (%)t 0 (-27 ; 45)** 
Postmethionine (pmol/L) 
Before treatment 63 (52; 111) 71 (52; 97) 63 (54; 111) 0.3Í 
During treatment 47 (33; 67) 39 (28 ; 82) 52 (30 ; 85) 0.21 
P-valuef <0.05 <0.05 <0.05 
Response to treatment (%)* -23 (-48 ; 3) -46 (-58 ; 15)** -27 (-62 ; 11 ) <0.05 
Normalization rate§ 6 of 11 (55%) 12 of 14 (86%) 6 of 12 (50%) 0.11 
* Values represent medians (minimum ; maximum); f P-value of the concentration differences between 
plasma homocysteine before and during treatment (Wilcoxon slgned-ranks test); ƒ Calculated from the 
concentrations of plasma homocysteine before [B] and during treatment [A], i.e. [A - BJ/fi]; § Expres-
ses the proportion of hyperhomocysteinemic women that achieved normal concentrations of plasma 
homocysteine during single vitamin treatment; *| P-value of the differences in plasma homocysteine 
concentrations and responses to treatment (Kruskal-Wallls one-way analysis of variance), and normali-
zation rates (uncorrected chi-square test) between the three treatment regimens; ** Significantly 
different as compared to the other treatment regimens (P < 0.05, Wilcoxon rank-sum test). 
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Pyndoxine Folic acid Folic acid 
250 mg daily 5 mg daily 1 mg daily 
single combined single combined single combined 
I II III I II III I II III 
Pyndoxine Folic acid Folic acid 
250 mg daily 5 mg daily 1 mg daily 
single combined single combined single combined 
I II III I II III I II III 
Figure B.I. The individual concentrations of fasting and postmethionine plasma homocysteine 
(upper and lower part, respectively) in the three treatment groups studied, i.e. pyndoxi­
ne, 250 mg daily, and folic acid, 5 and 1 mg daily, respectively. Depicted are values 
before single vitamin treatment (I; η = 37), during single vitamin treatment (II; η = 37), 
and during subsequent combined treatment of pyridoxine, 250 mg daily, and folic acid, 
1 or 5 mg daily (III; η = 8) The dotted horizontal lines represent the 97.5 percentile 
levels of premenopausal women with normal pregnancy outcome (Table 6.3). 
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Twelve out of 37 women failed to normalize their postmethionine plasma homocystei­
ne concentrations during initial treatment with either pyridoxine or folic acid. Eight 
women were subsequently treated with an oral combination of pyridoxine, 250 mg 
daily, and folic acid, 1 or 5 mg daily. They underwent a third oral methionine loading 
test at least four weeks after the start of the combined treatment. All eight subjects 
achieved normal concentrations of plasma homocysteine (normalization rate, 100%; 
Figure 8.1). The median fasting plasma homocysteine concentration during combined 
treatment [9 (minimum - maximum range, 7-13) pmol/L] was not significantly diffe­
rent from that during single treatment [11(6 - 33) pmol/L; Ρ = 0.11], whereas the 
median postmethionine plasma homocysteine concentration was significantly lower 
during combined treatment [38 (24 - 48) μπηοΙ/L] as compared to single treatment [64 
(53 - 85) μιτιοΙ/L]. 
During pyridoxine treatment a significant 20 percent decrease of the median serum 
folate concentration [before and during pyridoxine treatment, 11 (5 - 23) and 8 (5 -
16) nmol/L, respectively; η = 11], but no significant effects on the median levels of red 
cell folate and serum vitamin B12 were observed. During folic acid treatment no 
significant changes in the median concentrations of whole blood PLP and serum 
vitamin B12 were noticed (data not shown). 
DISCUSSION 
The present study reports the effects of pyridoxine and folic acid treatment on the 
plasma homocysteine concentrations prior to and six hours after standardized oral 
methionine loading in hyperhomocysteinemic women with adverse pregnancy out­
come. During pyridoxine treatment no significant effect on the median concentration 
of fasting homocysteine, but a significant reduction of that of postmethionine homo­
cysteine was observed (Table 8.3). Pyridoxine treatment has been studied in vascu­
lar patients with mild hyperhomocysteinemia [Brattström et al., 1990; Dudman et al., 
1993; Franken et al., 1994], as well as in healthy subjects with normal homocysteine 
concentrations [Brattström et al., 1988a]. These studies also have demonstrated not 
any significant change in the fasting homocysteine concentrations during pyridoxine 
treatment. This phenomenon may best be explained by the differences in the Michae-
lis constant («„,, i.e. the substrate concentration at which the reaction velocity equals 
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half the maximum velocity) of the enzymes involved in homocysteine metabolism 
[Finkelstein, 1990]. The K„, value of cystathionine ß-synthase (CBS, 1-25 mmol/L), 
which catalyzes the transsudation of homocysteine to cystathionine, is more than 
ten-fold higher than the K„, values of the enzymes involved in homocysteine remethy-
lation (U 0.06 mmol/L). This indicates that the homocysteine concentration in a 
fasting condition will be effected by the folate-dependent remethylation, and will be 
less influenced by the administration of pyridoxine, which is cofactor in the CBS 
reaction. 
Remarkably, we have noticed a significant 20 percent reduction of the median serum 
folate concentration during pyridoxine treatment. This phenomenon has only been 
reported in a few studies which observed a further decrease of low serum folate 
concentrations in some patients with CBS deficiency, who were treated with pyridoxi-
ne [Carson and Carré, 1969; Wilcken and Turner, 1973]. Theoretically, the homo-
cysteine-lowering effect of pyridoxine treatment may be counteracted by the 
homocysteine-increasing effect due to the pyridoxine-induced decrease of serum 
folate. 
During folic acid treatment, 1 as well 5 mg daily, a significant reduction of the median 
fasting plasma homocysteine concentration was observed (Table 8.3). The median 
postmethionine concentration of plasma homocysteine decreased by one-quarter 
during the 1 mg regimen, whereas this level decreased by 45 percent during the 
administration of 5 mg of folic acid, which difference was statistically significant. The 
median postmethionine plasma homocysteine response to folic acid, 5 mg daily, was 
also significantly larger as compared to pyridoxine treatment (Table 8.3). Folic acid 
has been reported as an effective means to reduce the elevated plasma concentra-
tions of homocysteine in patients with chronic renal insufficiency [Wilcken et al., 
1988], in uremic patients on chronic dialysis [Arnadottir et al., 1993], in renal trans-
plant recipients [Wilcken et al., 1981]. In healthy subjects, normal levels of blood 
homocysteine are also lowered by folic acid supplementation [Brattström et al., 1985; 
1988a]. Recently, folic acid treatment was demonstrated to be effective in vascular 
patients with impaired homocysteine metabolism [Dudman et al., 1993; Franken et 
al., 1994]. Dudman et al. (1993), in contrast to our present observation, reported no 
significant difference between the effects of single daily treatment for two weeks with 
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either pyridoxine, 100 mg, or folic acid, 5 mg. 
The major limitation of the present study results from its uncontrolled design. As a 
consequence, the observed changes in plasma homocysteine may in part be due to 
a statistical phenomenon called regression toward the mean. Another bias may result 
from the nonrandomized procedure. Patients' assignment towards either one of the 
three regimens was determined by their time of enrollment. Unfortunately, the pre-
treatment concentrations of fasting plasma homocysteine and red cell folate tended 
to be significantly different between the three groups studied (Table 8.3 and 8.2, 
respectively). The pretreatment concentrations of postmethionine plasma homocys-
teine and the other studied vitamins, however, were not significantly different be-
tween the three groups. Clearly, a randomized controlled study would be more 
appropiate to assess the true homocysteine-lowering effects of vitamins. 
In the present study, the median periods of treatment varied around 6 weeks. It may 
be questionable whether long-term treatment would induce further beneficial changes 
in plasma homocysteine concentrations. The difference in median postmethionine 
plasma homocysteine responses between the 1 and 5 mg regimen of folic acid could 
in part be the result of the limited duration of treatment. In this respect, the 
homocysteine-lowering effect of the combination of pyridoxine and folic acid may be 
due to either the addition of another vitamin, or the prolonged duration of the single 
treatment, or both. 
Hyperhomocysteinemia was recently observed to be associated with recurrent mis-
carriage and placental vasculopathy [Wouters et al., 1993; Goddijn-Wessel et al., In 
press]. Spontaneous abortion and placental infarction are morphologically characteri-
zed by common vascular changes, i.e. microthrombosis, vasospastic changes, fibrin 
depositions, and necrosis [Rushton, 1988; Rayne and Kraus, 1993]. Theoretically, 
homocysteine may act as a vascular damaging agent (Chapter 3). Therefore, recur-
rent miscarriage and placental vasculopathy may represent a common pathophysio-
logic phenomenon, although with different clinical manifestations. 
Periconceptional administration of folic acid, alone or in a combination with pyridoxine 
may reduce the elevated plasma homocysteine concentrations in women with adver-
se pregnancy outcome, and possibly favor their subsequent pregnancy outcome. A 
randomized controlled prevention trial should provide data to justify the routine use of 
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these vitamins in hyperhomocysteinemic women who wish to conceive. 
In conclusion, folic acid seems more effective in reducing elevated plasma homocys-
teine concentrations in women with adverse pregnancy outcome than pyridoxine. A 
randomized controlled study would be more appropiate to assess the true homo-
cysteine-lowering effects of these vitamins. 
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SUBSEQUENT PREGNANCY OUTCOME 
OF WOMEN WITH RECURRENT MISCARRIAGE 
AS RELATED TO THEIR HOMOCYSTEINE STATUS 
AND PERICONCEPTIONAL B-VITAMIN USE 
ABSTRACT 
Objective. To evaluate prospectively the effect of periconceptional B-vitamin treat-
ment on the outcome of the next pregnancy in women with recurrent miscarriage. 
Design. The homocysteine status of women with recurrent miscarriage was evalua-
ted by oral methionine loading test, and data on the outcome of the next pregnancy 
were collected. Ninety-five women were retrospectively classified in three groups by 
their homocysteine status at study entry and their periconceptional B-vitamin use, 
and pregnancy outcomes were compared. 
Results. Group I consisted of 23 hyperhomocysteinemic women who were treated 
with B-vitamins, group II of 17 normohomocysteinemic women who had used B-
vitamins as well, and group III of 55 normohomocysteinemic women who had not 
used any vitamins. The rate of livebirths was significantly higher in group I (83%) as 
compared to group III (53%). In hyperhomocysteinemic women, the rate of livebirths 
was highest in women without a previous successful pregnancy (11 of 11 ; 100%). 
Conclusion. Periconceptional B-vitamin use may favor women with recurrent miscar-
riage and hyperhomocysteinemia, especially those women without a previous suc-
cessful pregnancy. 
Wouters MGAJ, Hamilton CJCM, Blom HJ, Boers GHJ, Thomas CMG, Borm GF, Eskes TKAB. Peri-
conceptional B-vitamins as a treatment for recurrent spontaneous abortion associated with hyperhomo-
cysteinemia. Submitted. 
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INTRODUCTION 
Hyperhomocysteinemia was recently observed to be associated with recurrent mis­
carriage (Chapter 6) [Wouters et a l , 1993] Folic acid and pyridoxine, so-called B-
vitamms, may reduce high concentrations of plasma homocysteine in women with 
adverse pregnancy outcome (Chapter 8) It is unknown, however, whether B-vitamins 
improve subsequent pregnancy outcome 
OBJECTIVE 
To evaluate prospectively the effect of penconceptional B-vitamm treatment on the 
outcome of the next pregnancy in women with recurrent miscarriage 
DESIGN 
Between May 1991 and October 1993, 142 women with recurrent miscarriage were 
selected for homocysteine testing The selection criteria are listed in Table 4 1 Their 
homocysteine and vitamin status were evaluated by standardized oral methionine 
loading test 
For ethical reasons, all hyperhomocysteinemic women were treated with either 
pyridoxine, 250 mg daily, or folic acid, 1 or 5 mg daily, for at least four weeks in order 
to achieve normal concentrations of plasma homocysteine Patients' assignment 
towards either one of the three regimens was determined by their time of enrollment 
(Chapter 8) Women who remained hyperhomocysteinemic after single treatment 
received a combined treatment of both vitamins, in all cases resulting in normal 
concentrations of plasma homocysteine (Chapter 8) Hydrocobalamin, 1,000 pg 
intramuscularly once every month, was prescribed in cases of a subnormal concen­
tration of serum vitamin B12, ι e below 100 pmol/L (lowest value of premenopausal 
controls, Table 5 2) Subsequently, women were advised to continue their treatment 
at least throughout the first trimester of the next pregnancy Normohomocystememic 
women did not receive any vitamin prescription, though they were allowed to use 
extra vitamins voluntarily 
Between May and October 1994, all women (n = 142) were contacted by phone 
Data on sort, dose and period of vitamin use, as well as course and outcome of the 
next pregnancy were collected Pregnancies were classified as spontaneous abor-
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tion, ectopic pregnancy, stillbirth or livebirth. Women were retrospectively classified in 
three groups by their homocysteine status at study entry, and their B-vitamin use 
before and during the first trimester of the next pregnancy. Group I consisted of 
hyperhomocysteinemic women who were treated with B-vitamins, group II of normo-
homocysteinemic women who had used B-vitamins as well, and group III of normo-
homocysteinemic women who had not used any vitamins. 
STATISTICAL ANALYSIS 
Kruskal-Wallis one-way analysis of variance was used to analyze the quantitative 
differences between the three groups, followed by pairwise Wilcoxon rank-sum tests 
in case of a significant result. Chi-square test was used to compare the proportional 
differences between the three groups. In addition, relative risks of livebirth versus no 
livebirth were calculated, and are reported as relative incidences of livebirth including 
95% confidence intervals (95% CIs). P-values were two-tailed, and Ρ < 0.05 was 
considered statistically significant. 
RESULTS 
One hundred and thirty-eight women were questioned by phone, whereas four wo­
men were lost from follow-up. One hundred and six women (77%) had achieved at 
least one pregnancy [median 1 (minimum - maximum range, 1 - 3)]. The remaining 
32 women had failed to conceive and were excluded from analysis. The period of 
follow-up was not significantly different between women with and without subsequent 
pregnancy [26 (11 - 37) and 23 (11 - 37) months respectively, Ρ = 0.45]. 
Eleven out of 106 women could not be classified in either of three groups because of 
ongoing pregnancy (n = 2), or unknown or uncertain B-vitamin use (n = 9). As a 
result 95 women were classified as follows: 23 women as group I, 17 women as 
group II, and 55 women as group III. Table 9.1 summarizes the number of previous 
miscarriages and livebirths, period of preconceptional B-vitamin use, and age at 
conception in the respective groups. In group I, ten women were treated with folic 
acid, 1 mg (n = 4) or 5 mg (n = 6) daily, two women with pyridoxine, 250 mg daily, six 
women with a combination of folic acid, 1 mg (η = 1) or 5 mg (η = 5) daily, and pyri­
doxine, 250 mg daily, two women with hydrocobalamin, 1,000 pg intramuscularly 
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once every month, and three women with a combination of folic acid, 1 mg daily, and 
hydrocobalamin, 1,000 μ9 intramuscularly once every month In group II, 16 women 
had voluntarily used folic acid, 0 5 mg (η = 4), 1 mg (η = 1), or 5 mg (η = 11) daily, 
and one woman was prescribed hydrocobalamin, 1,000 pg intramuscularly once 
every month, by her general practitioner 
The concentrations of plasma homocysteine and blood vitamins at study entry are 
listed groupwise in Table 9 2 Due to the selection criterion, the median concentra­
tions of fasting and postmethionine plasma homocysteine were significantly higher in 
group I as compared to the other groups, whereas the median plasma homocysteine 
concentrations were not significantly different between group II and III (fasting and 
postmethionine plasma homocysteine, Ρ = 0 86 and Ρ = 0 17 respectively) The 
median serum and red cell folate concentrations were significantly lower in group I as 
compared to the other groups, whereas the median folate concentrations were not 
significantly different between group II and III (serum and red cell folate, Ρ = 0 80 and 
Ρ = 0 20 respectively) B-vitamin deficiency was not present in anyone of the women 
studied, except for folate deficiency due to celiac disease in one woman of group I 
The respective outcomes of the next pregnancy are presented in Table 9 3 The rate 
of livebirths was higher in group I compared to group II and III The difference, howe­
ver, was only statistically significant between group I and III The relative incidence of 
Table 9.1. Selection entena and charactenstics of group I, II. and III * 
Homocysteine status 
B-vitamm use 
Group I 
N = 23 
hyperhomo-
cystememic 
yes 
Group II 
N = 1 7 
normohomo-
cysteinemic 
yes 
Group III 
N = 55 
normohomo-
cysteinemic 
no 
Pt 
No of previous miscarriages 3 (2 - 5) 3 (2 - 6) 3 (2 - 9) 
No of previous livebirths 1 (0 - 3) 0 (0 - 1 ) 0 (0 - 3) 
Period of preconcepbonal B-
vitamm use (mo) 4(2-15) 4(1-12) 
Age at conception (y) 33 (24 - 38) 33 (29 - 36) 33 (27 - 42) 
* Values represent medians (minimum - maximum), t P-value of difference (Kruskal-Wallis one-way 
analysis of vanance) 
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Table 9.2. Concentrations of plasma homocysteine and blood vitamins at study entry in group I 
(hyperhomocysteinemic women with B-vitamm use), II and III (normohomocystememic 
women with and without B-vitamm use, respectively)* 
Fasting plasma 
homocysteine (pmol/L) 
Postmethionme plasma 
homocysteine (pmol/L) 
Whole blood PLP(nmol/L) 
Serum folate (nmol/L) 
Red cell folate (nmol/L) 
Serum vitamin B12 (pmol/L) 
Group I 
N = 23 
1 6 ( 1 0 - 3 5 » 
60(42-111)* 
42(21-180) 
11 ( 1 - 2 0 ) | 
400 (43 - 670)t 
210(66-460) 
Group II 
N = 17 
11 (6-15) 
39 (23 - 47) 
50 (27 - 77) 
12(7-53) 
550(280-1600) 
250 (84 - 490) 
Group III 
N = 55 
10(3-15) 
32(19-50) 
43 (29 - 77) 
13(5-43) 
510 (250 -1600) 
270 (73 - 1400) 
P\ 
< 0 05 
< 0 05 
0 41 
< 0 05 
< 0 05 
0 10 
* Values are presented as medians (minimum - maximum), f P-value of difference (Kruskal-Walhs one­
way analysis of vanance), t Significantly different as compared to the other groups (Wilcoxon rank-sum 
test) 
hvebirth in group I was 1 28 (95% CI, 0 86 -1 90) and 1 57 (95% CI, 1 15 - 2 14) as 
compared to group II and III respectively The relative incidence of hvebirth in group II 
was 1 23 (95% CI, 0 80 -1 89) as compared to group III 
In hyperhomocysteinemic women, the rate of livebirths was highest in women without 
a previous hvebirth (Table 9 4) Here the relative incidence of hvebirth in group I was 
1 75 (95% CI, 1 11 - 2 75) and 2 12 (95% CI, 1 50 - 2 99) when compared to group II 
Table 9.3. Pregnancy outcome in group I (hyperhomocysteinemic women with B-vitamin use), II 
and III (normohomocystememic women with and without B-vitamm use, respectively)* 
Livebirthf 
No hvebirth 
Spontaneous abortion 
Ectopic pregnancy 
Stillbirth 
Group I 
N = 2 3 
19(83%) 
4 (17%) 
4 
0 
0 
Group II 
N = 17 
11 (65%) 
6 (35%) 
6 
0 
0 
Group III 
N = 55 
29 (53%) 
26 (47%) 
24 
2 
0 
* Values are presented as numbers (proportions), t Chi-square - 6 2, Ρ < 0 05 (all groups) 
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Table 9.4. Pregnancy outcome in group I (hyperhomocysteinemic women with B-vitamin use), II 
and III (normohomocysteinemic women with and without B-vitamin use, respectively) 
in relation to previous pregnancies without or with previous livebirth* 
Without previous livebirth: 
Livebirtht 
No livebirth 
With previous livebirth: 
Livebirth§ 
No livebirth 
Group 1 
N = 23 
11(100%) 
0 (0%) 
8 (67%) 
4 (33%) 
Group II 
N = 17 
8 (57%) 
6 (43%) 
3(100%) 
0 (0%) 
Group III 
N = 55 
17 (47%) 
19(53%) 
12 (63%) 
7 (37%) 
* Values are presented as numbers (proportions); t Chi-square = 9.7, Ρ < 0.05 (all groups without 
previous livebirth), § Chi-square = 1.6, Ρ = 0.45 (all groups with previous livebirth). 
and III, respectively. In women with a previous successful pregnancy the rates of 
livebirths were not significantly different (Table 9.4). 
DISCUSSION 
This study demonstrates for the first time that women with recurrent miscarriage and 
hyperhomocysteinemia may benefit from B-vitamin treatment. Hyperhomocysteine­
mic women who were treated with B-vitamins before and during the first trimester of 
their next pregnancy (group I) had a significantly higher rate of livebirths as compared 
to those who were normohomocysteinemic and had not used any vitamins pericon-
ceptionally (group III). The rate of spontaneous abortions in hyperhomocysteinemic 
women who were treated with B-vitamins (4 out of 23, 17%; Table 9.3) almost equals 
the early loss rate as observed in the general population, which is consistently repor­
ted as 12 to 15% (reviewed by Stirrat, 1990a). 
The question arises how the use of B-vitamins improves subsequent pregnancy 
outcome in hyperhomocysteinemic women. In our opinion two theories can be postu­
lated. The first is based on the beneficial effect of reduction and/or normalization of 
high concentrations of plasma homocysteine. In an earlier study, we discussed that 
increased concentrations of maternal plasma homocysteine may cause early damage 
of decidual or chorionic vessels leading to disturbed implantation of the conceptus 
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[Wouters et al., 1993]. In the present study, all hyperhomocysteinemic women had 
achieved normal concentrations of plasma homocysteine following treatment with B-
vitamins before they conceived. In all cases studied, treatment was continued during 
subsequent pregnancy, at least throughout the first trimester. In agreement with other 
reports [Kang et al., 1986b; Andersson et al., 1992b], we observed that during the 
pregnancies studied plasma homocysteine concentrations stayed within the normal 
range, and even tended to decrease [Wouters MGAJ et al., unpublished data]. A 
second mechanism by which B-vitamin use may improve pregnancy outcome is the 
amelioration of a nutritional deficiency and/or metabolic derangement of B-vitamins. 
Malnutrition and malabsorption of folate and vitamin B12, or inherited enzyme defects 
involved in the metabolism of these vitamins may result in hyperhomocysteinemia 
[Rosenblatt, 1989; Fenton and Rosenberg, 1989]. In the present study, serum and 
red cell folate were significantly lower in hyperhomocysteinemic women as compared 
to women of the other groups (Table 9.2), although folate deficiency was only present 
in one woman with celiac disease. This finding may indicate a derangement of folate 
metabolism in a substantial proportion of hyperhomocysteinemic women. 
A successful outcome of the next pregnancy after recurrent miscarriage is related to 
a lower number of previous spontaneous abortions [Stirrat, 1990a; Quenby and 
Farquharson, 1993]. Furthermore, secondary aborters may have a better outcome 
than primary aborters [Stirrat, 1990a; Quenby and Farquharson, 1993]. In this res-
pect, the number of previous miscarriages and livebirths in the three groups studied 
did not differ significantly from each other (Table 9.1). The mechanism by which 
obstetric history might influence the outcome of the next pregnancy is not known. It is 
thought that recurrent aborters with a higher number of previous spontaneous abor-
tions and/or without a previous livebirth are more likely to suffer from any persistent 
underlying etiologic factor. The elimination or correction of this factor would allow 
early pregnancy to continue [Regan et al.,1989]. Remarkably, we found that B-vita-
min use was especially favorable in hyperhomocysteinemic women who did not pre-
viously deliver a liveborn child (Table 9.4). In our opinion, this finding may support the 
hypothesis about a causal relationship between hyperhomocysteinemia and sponta-
neous abortion at least in some cases of recurrent miscarriage (Chapter 6) [Wouters 
et al., 1993]. 
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In the present study, normohomocysteinemic women using B-vitamins (group II) had 
a higher rate of livebirths as compared to those who were not (group III), although the 
difference was not statistically significant (Table 9.3). This finding suggests that B-
vitamin use improves pregnancy outcome in normohomocysteinemic women as well. 
At present, we have no data on the subsequent pregnancy outcome in hyperhomo-
cysteinemic women who were not B-vitamin treated. A large prospective randomized 
controlled trial should adequately quantify the beneficial effect of B-vitamin use in 
women with recurrent miscarriage in relation to their homocysteine status. In the 
Netherlands, however, this option is definitely out of reach. Dutch women planning to 
conceive are currently advised to use folic acid periconceptionally, 0.5 mg per day, in 
order to prevent the occurrence of NTD [Voedingsraad/Gezondheidsraad, 1993]. As 
a consequence, future prospective studies will be limited to a merely observational 
design. 
In conclusion, periconceptional B-vitamin use may favor women with recurrent mis-
carriage and hyperhomocysteinemia, especially those women without a previous 
successful pregnancy. 
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LONGITUDINAL OBSERVATION OF HOMOCYSTEINE 
STATUS IN WOMEN WITH RECURRENT MISCARRIAGE 
ABSTRACT 
Objective. To compare the homocysteine status of women with recurrent miscarriage 
before and after a subsequent pregnancy. 
Design. Seventeen women with recurrent miscarriage were examined by oral methio-
nine loading test before conception and after the completion of a subsequent preg-
nancy. Hyperhomocysteinemia was initially present in nine women. Normal plasma 
homocysteine concentrations were found in the remaining eight subjects. Plasma 
homocysteine concentrations before and after pregnancy were compared. 
Results. Overall, in 14 out of 17 women plasma homocysteine concentrations were 
essentially the same before and after pregnancy. No significant changes were obser-
ved in the median concentrations of plasma homocysteine and blood vitamins as 
measured by the initial and repeat test. 
Conclusion. Plasma homocysteine levels before and after pregnancy are about iden-
tical in most women with recurrent miscarriage. 
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INTRODUCTION 
In healthy women, plasma homocysteine concentrations have been observed to 
decrease during pregnancy, and to return to prepregnant levels post partum [Kang et 
al., 1986b; Andersson et al., 1992b]. In women with recurrent miscarriage, it is not 
known whether the homocysteine status established after pregnancy will be the same 
as before pregnancy. 
OBJECTIVE 
To compare the homocysteine status of women with recurrent miscarriage before 
and after a subsequent pregnancy. 
DESIGN 
Seventeen women with recurrent miscarriage were examined by oral methionine 
loading test before and after a subsequent pregnancy. Hyperhomocysteinemia was 
initially present in nine women. Normal plasma homocysteine concentrations were 
found in the remaining eight subjects. Hyperhomocysteinemic women were prescri-
bed B-vitamins before and throughout the first trimester of pregnancy, whereas 
normohomocysteinemic women did not use any vitamins, except for one woman who 
chose to use extra B-vitamins. Seven out of nine women with initial hyperhomocystei-
nemia had a successful pregnancy. The same was true for six out of eight women 
with a primary normal homocysteine status. Vitamin use was discontinued after the 
completion of pregnancy. Repeat tests were performed at least three months after 
pregnancy and under the same conditions as initial tests. 
STATISTICAL ANALYSIS 
Wilcoxon signed-ranks test was used to analyze the differences between paired 
variables. 
RESULTS 
The median time interval between the initial and repeat test was 31 months (range, 
16 - 39). Figure 10.1 depicts the individual changes of plasma homocysteine concen-
trations in the studied subgroups. 
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Figure 10.1. Individual concentrations of fasting and postmethionine plasma homocysteine in nine 
hyperhomocysteinemic and eight normohomocysteinemic women (upper and lower 
part, respectively) as measured by the initial and repeat test. The dotted lines repre­
sent the 97.5 percentile level of plasma homocysteine in premenopausal controls 
(Table 6.3). 
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Fasting plasma homocysteine concentrations remained elevated in four out of five 
women, and stayed normal in 10 out of 12 Postmethionine plasma homocysteine 
concentrations remained elevated in seven out of nine women, and stayed normal in 
seven out of eight women Overall, in 14 out of 17 women plasma homocysteine 
concentrations were essentially the same before and after pregnancy 
No significant changes were observed in the median concentrations of plasma homo­
cysteine and blood vitamins as measured by the initial and repeat test (Table 10 1) 
Figure 10 2 shows a longitudinal plot of the individual concentrations of fasting plas­
ma homocysteine in six women with initial hyperhomocystememia Depicted are 
levels at the initial test, before and during early pregnancy, and at the repeat test 
During B-vitamm treatment, plasma homocysteine concentrations seemed to decrea­
se, whereas during pregnancy no further decline was observed At the repeat test, 
the concentrations of plasma homocysteine had returned to their initial levels 
Table 10.1. Concentrations of plasma homocysteine and blood vitamins as measured by the initial 
and repeat test 
Women of the study group P-valuet 
N = 17 
Initial test Repeat test 
Fasting plasma homocysteine (pmol/L) 13(7-35) 14(9-28) 0 91 
Postmethionine plasma homocysteine (μιποΙ/Ι_) 51 (23 -111) 49 (25 - 88) 0 37 
Serum folate (nmol/l) 14(5-33) 11(7-28) 0 21 
Red cell folate (nmol/L) 490 (240 - 840) 520 (320 - 880) 0 34 
Serum vitamin B12 (pmol/L) 200(100-390) 235(110-330)t 0 92 
Whole blood PLP § (nmol/L) 38 (21- 72)t 42(22-61) 0 21 
* Values are given as medians (minimum - maximum), ƒ N = 16, f Wilcoxon signed-ranks test, § Pyn-
doxal-S'-phosphate (an active form of vitamin B6) 
DISCUSSION 
In the present study, the homocysteine status of women with recurrent miscarriage 
was evaluated by oral methionine loading test before conception and after the com­
pletion of a subsequent pregnancy Fasting and postmethionine plasma homocystei­
ne concentrations were essentially the same in most women studied Similarly, per-
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Figure 10.2. Longitudinal plot of the individual concentrations of fasting plasma homocysteine m six 
women with initial hypemomocysteinemia Depicted are levels at the initial test, before 
and dunng eariy pregnancy, and at the repeat test The dotted lines are hypothetical 
sistent hyperhomocysteinemia was found in most untreated patients with premature 
cerebral and peripheral occlusive arterial disease one year after their first examina­
tion [Brattstrom et a l , 1990] 
As depicted in Figure 10 1, the individual plasma homocysteine concentrations of the 
repeat test were more likely to be lower in case of high initial values and higher in 
case of low initial values This observation probably reflects regression toward the 
mean, and is due to intra-individual variations in plasma homocysteine levels In 
agreement with this phenomenon, the median plasma homocysteine concentrations 
of the initial and repeat test were not significantly different (Table 101) In addition, 
there were no significant differences between the blood vitamins studied as well 
(Table 101) 
Andersson et al (1992b) observed a decrease of normal plasma homocysteine levels 
in pregnant women It is hypothesized that increased concentrations of serum 17ß-
estradiol, as in pregnancy, enhance the transsudation and/or remethylation of 
homocysteine (Chapter 5) Not surprisingly, the elevated concentrations of fasting 
plasma homocysteine seemed to decrease during B-vitamin treatment (Figure 10 2) 
No further decline, however, was observed during pregnancy This was probably due 
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to a maximum turnover of homocysteine resulting from B-vitamin treatment. After the 
completion of pregnancy and discontinuation of B-vitamin use, a return to the initial 
concentrations was noticed (Figure 10.2). This observation suggests that the homo-
cysteine status may be altered by temporary conditions such as pregnancy or vitamin 
treatment, but is mainly determined by other factors, e.g. genetic. 
It is concluded that plasma homocysteine levels before and after pregnancy are 
about identical in most women with recurrent miscarriage. 
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HOMOCYSTEINE AND VITAMIN STATUS 
OF WOMEN WITH PLACENTAL VASCULOPATHY 
ABSTRACT 
Objective. To establish the prevalence of hyperhomocysteinemia in women with a 
history of placental vasculopathy, i.e. abruption or infarction of the placenta. 
Design. Forty-six women with normal pregnancy outcome (controls) and 84 women 
with placental vasculopathy (study group) were selected. The homocysteine status 
was studied by a standardized oral methionine loading test. Hyperhomocysteinemia 
was defined as a fasting and/or postmethionine plasma homocysteine concentration 
above the estimated 97.5 percentile level of the controls. The vitamin status was 
investigated by the measurement of serum and red cell folate, serum vitamin В12, 
and whole blood pyridoxal-5'-phosphate (PLP, an active form of vitamin B6) in a 
fasting state. 
Results. Hyperhomocysteinemia was diagnosed in 4 controls (9%) and 26 women of 
the study group (31%, Ρ < 0.05). The median concentrations of the vitamins studied 
were significantly lower in women of the study group as compared to the controls, 
except for red cell folate, where the median concentration was comparable in both 
groups. The median concentration of fasting plasma homocysteine, unlike post­
methionine plasma homocysteine, was significantly higher in women who experien­
ced placental vasculopathy in their first pregnancy than in women who had the same 
event after one or more uncomplicated pregnancies. 
Conclusion. Hyperhomocysteinemia is associated with placental vasculopathy. 
Goddijn-Wessel TAW, Wouters MGAJ, Van der Molen EF, Spuijbroek MDEH, Steegers-Theunissen 
RPM, Blom HJ, Boers GHJ, Eskes TKAB. Hyperhomocysteinemia: A risk factor for placental abruption 
or infarction. In press. 
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INTRODUCTION 
It was recently demonstrated that hyperhomocysteinemia is associated with recurrent 
miscarriage (Chapter 6) [Wouters et al., 1993]. It is unknown, however, how elevated 
concentrations of plasma homocysteine may cause early pregnancy loss. Theoreti-
cally, homocysteine may be toxic to the developing embryo and/or fetus (Chapter 3). 
In this respect, it is interesting that neural tube defects (NTDs) are the most common 
group of malformations identified in tissue specimens from spontaneous abortion 
[Creasy and Alberman, 1976], and that the development of NTD in the offspring has 
been associated with hyperhomocysteinemia in the mother [Steegers-Theunissen et 
al., 1990a; 1994]. Secondly, homocysteine may act as an atherogenic and thrombotic 
agent in chorionic, decidual and placental vessels, leading to disturbed implantation 
of the conceptus in the first trimester, or placental abruption and/or infarction in a 
later stage of pregnancy. Microthrombosis, vasospastic changes, fibrin depositions, 
and necrosis are common morphologic features in tissue specimens from spontane-
ous abortion as well as placental infarction [Rushton, 1988; Rayne and Kraus, 1993]. 
The present study was undertaken to examine a possible relationship between 
placental vasculopathy, i.e abruption or infarction of the placenta, and hyperhomo-
cysteinemia. 
OBJECTIVE 
To establish the prevalence of hyperhomocysteinemia in women with a history of 
placental vasculopathy. 
DESIGN 
Forty-six premenopausal women with normal pregnancy outcome (controls) and 84 
women with placental abruption or infarction (study group) were selected. Some 
characteristics of the control and study group are listed in Table 11.1. 
The selection criteria of the control group are listed in Table 4.1. Placental abruption 
and infarction were defined by clinical, laboratory and histologic standards. The 
diagnosis of placental abruption was based on either the combined presence of a 
tender, hypertonic uterus and disseminated intravascular coagulation, and/or the 
histologic observation of a retroplacental hematoma with/without signs of infarction. 
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Tabi» 11.1. Characteristics of the control and study group* 
Age (y) 
Body weight (kg) 
Number of pregnancies 
Pregnancy outcome 
Miscarriage 
Induced abortion 
Ectopic pregnancy 
Fetal death 
Live birth 
Control group 
N = 46 
36(27-44) 
60(43-80) 
2 (1 -4 ) 
ot 
0(0-1 ) 
ot 
ot 
2(1 -4 ) 
Study group 
N = 84 
32(22-45) 
64 (42 -120) 
2 ( 1 - 6 ) 
0 (0 - 3) 
0 (0 -1 ) 
0 (0 -1 ) 
1 (0 -3 ) 
0 (0 - 3) 
* Values represent medians (minimum - maximum), t Defined by selection criteria (Table 4.1). 
Placental infarction was diagnosed if the placenta was characterized by circumscri-
bed areas of villous necrosis combined with a stillborn fetus or a severely growth-
retarded child, i.e. having a birth weight below the 10th percentile for gestational age. 
Data on clinical and laboratory features were collected by interview and hospital 
records. Histologic data were drawn from various pathologists' reports. Forty-four 
women (52%) had experienced abruption, whereas the remaining 40 women (42%) 
had suffered from infarction of the placenta (as a first event). 
The homocysteine status was studied by a standardized oral methionine loading test 
(Chapter 4). Hyperhomocysteinemia was defined as a fasting and/or postmethionine 
plasma homocysteine concentration above the estimated 97.5 percentile level of the 
controls. The vitamin status was investigated by the measurement of fasting concen-
trations of serum and red cell folate, serum vitamin B12, and whole blood pyridoxal-
5'-phosphate (PLP, an active form of vitamin B6). 
STATISTICAL ANALYSIS 
In controls, the 97.5 percentile levels of plasma homocysteine and blood vitamins 
were calculated as means + 1.96 standard deviations after log transformation. Wil-
coxon rank-sum test was used to analyze the quantitative differences, and uncorrec-
ted chi square test to analyze the proportional differences between the two groups 
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studied. Spearman's rank correlation was used to measure the associations between 
variables. P-values were two-tailed, and Ρ < 0.05 was statistically significant. 
RESULTS 
Figure 11.1 depicts the individual concentrations of fasting and postmethionine 
plasma homocysteine in the control and study group, respectively. In the control 
group, fasting plasma homocysteine concentrations ranged from 6 to 19 μηηοΙ/L, and 
postmethionine plasma homocysteine concentrations from 20 to 55 μιηοΙ/L. The 97.5 
percentile levels of fasting and postmethionine plasma homocysteine in controls were 
calculated as 15 and 51 μΓΠθΙ/L, respectively. In the study group, fasting plasma 
homocysteine concentrations varied from 6 to 36 pmol/L, and postmethionine plasma 
homocysteine concentrations from 16 to 97 μπτιοΙ/L. Hyperhomocysteinemia, i.e. 
fasting plasma homocysteine above 15 μτηοΙ/L and/or postmethionine plasma 
homocysteine above 51 μηιοΙ/L, was present in 4 of 46 (9%) controls and 26 of 84 
(31 %) women of the study group (Table 11.2; uncorrected chi square, 8.3; Ρ < 0.05). 
The median concentrations of plasma homocysteine and blood vitamins are presen­
ted in Table 11.3. Median fasting and postmethionine plasma homocysteine were sig­
nificantly higher in the study group as compared to the control group. The median 
concentrations of the vitamins studied were significantly lower in women of the study 
group as compared to the controls, except for red cell folate, where the median 
concentration was comparable in both groups. 
In the control as well as study group, fasting and postmethionine plasma homocystei­
ne were significantly and positively correlated (r = + 0.66 and r = + 0.61, respective­
ly). Table 11.4 lists the associations between plasma homocysteine and blood 
vitamins in women of the control and study group. 
The median concentrations of fasting and postmethionine plasma homocysteine were 
not significantly different between the subgroups classified either by the type of the 
first event or the number of events (Table 11.5). The median concentration of fasting 
plasma homocysteine, unlike postmethionine plasma homocysteine, was significantly 
higher in women who experienced abruption or infarction in their first pregnancy than 
in women who had the same event after one or more uncomplicated pregnancies. 
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Figure 11.1. Individual concentrations of fasting and postmethionine plasma homocysteine in 
women of the control (n = 46) and study group (n = 84). The dotted horizontal lines 
represent the 97.5 percentile control levels of fasting and postmethionine plasma 
homocysteine, 15 and 51 pmol/L, respectively. 
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Table 11.2. Prevalence of hyperhomocystememia in women of the control and study group as 
related to the level of fasting and postmethiomne plasma homocysteine' 
Fasting plasma Postmethiomne plasma Control group Study group 
homocysteine homocysteine N = 46 N = 84 
Normal Normal 42(91%) 58(69%) 
High Normal 3(7%) 11(13%) 
Normal High 1 (2%) 5 (6%) 
High High 0 (0%) 10(12%) 
* Values represent numbers (proportions). 
DISCUSSION 
The major finding of the present study is a high prevalence of hyperhomocysteinemia 
in women who experienced placental abruption or infarction. This result confirms an 
earlier preliminary report from our laboratory [Steegers-Theunissen et al., 1992a]. 
Placental abruption, a life-threatening event for the mother and her child, is thought 
to be the result of sudden rupture of the spiral artery. It often develops simultaneous-
ly with placental infarction which also markedly increases the risk of fetal or neonatal 
death [MacPherson, 1991] Infarction of the placenta is predominantly the result of 
spiral artery occlusion in the myometrium or decidua Histologic examination of the 
spiral arteries in placental infarction usually reveals one ore more signs of vasculopa-
Table 11.3. Concentrations of plasma homocysteine and blood vitamins in women of the control 
and the study group* 
Fasting plasma homocysteine (pmol/L) 
Postmethiomne plasma homocysteine (pmol/L) 
Serum folate (nmol/L) 
Red cell folate (nmol/L) 
Serum vitamin B12 (pmol/L) 
Whole blood PLP (nmol/L) 
Control group Study group P-value 
N = 46 N = 84 t 
9(6-19) 11(6-36) <0 05 
29 (20 - 55) 37 (16 - 97) < 0 05 
14(7-25) 12(3-35) < 0 05 
500(310-1000) 510(150-1300) 0 95 
270 (100 - 580) 230 (60 - 620) < 0 05 
53 (27 - 160) 42 (18 - 85) < 0 05 
* Values represent medians (minimum - maximum); t Wilcoxon rank-sum test 
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Table 11.4. Associations between plasma homocysteine and blood vitamins in women of the 
control and study group* 
Control group 
N = 46 
Fasting plasma 
homocysteine 
Postmethionine 
plasma 
homocysteine 
Study group 
N = 84 
Fasting plasma 
homocysteine 
Postmethionine 
plasma 
homocysteine 
Serum folate -0 43t - 0 48t -0 57t - 0 41f 
Red cell folate + 0 07 + 0 1 1 -0 47+ - 0 24+ 
Serum vitamin B12 + 0 08 + 0 07 -0 35+ - 0 1 8 
Whole blood PLP + 0 03 + 0 04 - 0 1 1 - 0 1 1 
* Values represent Spearman's rank correlation coefficients, t Statistically significant (P<0 05) 
Table 11.5. Concentrations of fasting and postmethionine plasma homocysteine in women of the 
study group as classified by the type and pregnancy number of the first event, and the 
number of events* 
Fasting plasma Postmethionine plasma 
homocysteine (μπιοΙ/L) homocysteine (μπΊθΙ/L) 
Type of first event 
Abruption (n = 44) 12 (7 - 36) 
Infarction (n = 40) 11(6-35) 
P-valuet 0 28 
Pregnancy number (G) of first event 
G = 1 (n = 46) 
G > 1 (n = 38) 
P-valuef 
Number of events 
One(n = 66) 11(6-36) 38(22-97) 
Two or more (n= 18) 13(6-35) 36(16-78) 
P-valuet 021 046 
* Values represent medians (minimum - maximum), t Difference between subgroups (Wilcoxon rank-
sum test) 
38 (23 - 97) 
36 (16 - 87) 
0 60 
12 (6 - 36) 
10(6-29) 
004 
39 (23 - 87) 
35 (16 - 97) 
0 13 
96 Chapter 11 
thy, i.e. atherosis, narrowing, necrosis and thrombosis [MacPherson, 1991; Rayne 
and Kraus, 1993]. 
The hypothesis that elevated concentrations of plasma homocysteine affect the 
placenta is supported by the reported case of a woman with homocystinuria in whom 
four pregnancies resulted in intrauterine fetal death with multiple infarctions in the 
placenta [Hilden et al., 1972]. As yet, the question how high levels of homocysteine 
may cause vasculopathy of the spiral arteries is unanswered. Abnormalities of endo-
thelial cells, platelets, clotting factors, serum lipids, or disorders in the complex 
interaction of these factors have been held responsible for the vascular damage and 
thrombogenesis in hyperhomocysteinemia [Mudd et al., 1989; Kang et al., 1992; 
Ueland et al., 1992]. In human, the concentration of homocysteine in plasma is 
probably dependent on the extracellular homocysteine export and on the capacity of 
homocysteine degradation in mainly the liver and kidney [Finkelstein, 1990; Ueland et 
al., 1992]. In endothelial cells in vitro, a delicate equilibrium exists between homocys-
teine export and degradation. Any disequilibrium resulting in hyperhomocysteinemia 
may contribute to the vulnerability of the endothelial cell [Van der Molen et al., 1995]. 
Hyperhomocysteinemia may result from disorders in the transsulfuration or remethy-
lation of homocysteine [Mudd et al., 1989]. Enzymatic defects or vitamin deficiencies 
due to malabsorption or malnutrition may interfere with both routes [Rosenblatt, 
1989; Fenton and Rosenberg, 1989]. Hibbard (1964) has already suggested a higher 
prevalence of defective folate metabolism in women with placental abruption 
compared to controls, as indicated by their excessive formimino-glutamic acid 
excretion after histidine loading. In the present study, the median levels of serum 
folate, serum vitamin B12 and whole blood PLP were significantly lower in women of 
the study group compared to those of the control group (Table 11.3). In addition, 
serum and red cell folate were observed to be significantly and negatively associated 
with plasma homocysteine (Table 11.4). Placental vasculopathy may, at least in 
some cases, result from a primary nutritional deficit of folate and/or vitamin B12. 
In the present study, the median concentration of fasting plasma homocysteine, 
unlike postmethionine plasma homocysteine, was significantly higher in women who 
experienced abruption or infarction in their first pregnancy than in women who had 
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the same event after one or more uncomplicated pregnancies. It is speculated that 
higher levels of plasma homocysteine result in placental malfunction earlier in 
maternal life. It can be argued, however, whether the difference in median plasma 
homocysteine concentrations of only two micromoles per liter will be of clinical 
significance. 
Pyridoxine and/or folic acid administration have been reported to reduce plasma 
homocysteine concentrations in vascular patients with hyperhomocysteinemia 
[Brattström et al., 1990; Dudman et al., 1993; Franken et al., 1994; Van den Berg et 
al., 1994], as well as in hyperhomocysteinemic women with adverse pregnancy 
outcome (Chapter 8). It is not known whether biochemical normalization of hyperho-
mocysteinemia by periconceptional folate administration will favor pregnancy 
outcome in women with placental vasculopathy. A randomized controlled prevention 
trial should provide the answer to this important question. 
In conclusion, hyperhomocysteinemia is associated with placental vasculopathy. 
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EPILOGUE 
SUGGESTIONS FOR FUTURE RESEARCH 
In a patient-control study, we have established that hyperhomocysteinemia is 
associated with recurrent miscarriage (Chapter 6). The mechanism by which elevated 
concentrations of plasma homocysteine may cause early pregnancy loss, however, is 
not known. Theoretically, homocysteine may be toxic to the developing embryo 
and/or fetus (Chapter 3). It is interesting that neural tube defects (NTDs) are the most 
common group of malformations identified in tissue specimens from spontaneous 
abortion [Creasy and Alberman, 1976], and that the development of NTD in the 
offspring has been associated with hyperhomocysteinemia in the mother [Steegers-
Theunissen et al., 1990a; 1994; Mills et al., 1995]. Secondly, homocysteine may act 
as an atherogenic and thrombotic agent in chorionic, decidual and placental vessels, 
leading to disturbed implantation of the conceptus in the first trimester, or placental 
abruption and/or infarction in a later stage of pregnancy. Microthrombosis, vasospas-
tic changes, fibrin depositions, and necrosis are common morphologic features in 
tissue specimens from spontaneous abortion as well as placental infarction [Rushton, 
1988; Rayne and Kraus, 1993]. In line with the latter hypothesis, hyperhomocysteine-
mia was found to be associated with placental vasculopathy (Chapter 11). In this 
respect, a large field of interest awaits exploration. In vitro studies of homocysteine 
may elucidate its embryotoxic potency, or its vascular damaging effect in early and 
late placentation. Morphologic studies of tissue specimens of spontaneous abortion 
or placental abruption/infarction may identify histologic features possibly characteris-
tic for hyperhomocysteinemia. Finally, animal in vivo studies may be suitable to 
evaluate the effect of experimentally induced hyperhomocysteinemia on subsequent 
pregnancy outcome, either treated or untreated. 
Hyperhomocysteinemia is a well-established and useful marker of deranged homo-
cysteine metabolism. However, some limitations must be considered. We have 
defined hyperhomocysteinemia according to common though arbitrary criteria, based 
on the assumption of a certain but low prevalence of hyperhomocysteinemia among 
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controls. In addition, the use of hyperhomocysteinemia as a classifying parameter 
implicates an on-off phenomenon, i.e. hyperhomocysteinemia is present or not. It 
may well be possible, however, that the odds for recurrent miscarriage continuously 
increases with the higher concentrations of plasma homocysteine, as demonstrated 
in a recent study of patients with coronary artery disease [Pancharuniti et al., 1994]. 
Future studies are suggested to use plasma homocysteine concentrations rather 
than hyperhomocysteinemia in order to assess the risk for recurrent miscarriage. 
We have demonstrated that serum and red cell folate, and serum vitamin B12 are 
significant determinants of plasma homocysteine in women with recurrent miscarria-
ge (Chapter 6). From our results, we cannot exclude the possibility that hyperhomo-
cysteinemia is merely a marker of another underlying cause for recurrent miscarria-
ge, such as impaired folate and/or cobalamin metabolism. Future studies on the 
etiology of recurrent miscarriage should consider vitamin deficiencies as well. 
Next to high homocysteine levels, decreased remethylation of homocysteine may 
result in low methionine levels. Methionine is the precursor of S-adenosylmethionine, 
which is the universal methyl group donor in transmethylation reactions and thus 
essential to normal embryonic growth and development. Theoretically, recurrent 
miscarriage in women with hyperhomocysteinemia may result from inadequate 
methionine supply. Interestingly, methionine supplementation has been demonstra-
ted to prevent NTDs in cultured rat embryos [Coelho et al., 1989; Coelho and Klein, 
1990; Van Aerts et al., 1994]. In addition, methionine supplements have been found 
to improve reproductive outcomes in monkeys with histories of reproductive failure 
[Klein et al., 1993]. So far, methionine deficiency as a cause for recurrent miscarriage 
has not been under study, but warrants serious interest. 
Reduced cystathionine ß-synthase (CBS) activity and thermolabile 5,10 methylenete-
trahydrofolate reductase (MTHFR) were present in only a minor fraction of women 
with recurrent miscarriage and hyperhomocysteinemia (Chapter 7). This may indicate 
a genetic predisposition to hyperhomocysteinemia, at least in some women with 
recurrent miscarriage. MTHFR-related DNA mutation studies may reveal a genetic 
risk factor for recurrent miscarriage, as was recently demonstrated in NTD affected 
children and their mothers [Van der Put et al., 1995]. In this respect, molecular 
genetic studies in trophoblast cells from tissue specimen may demonstrate if 
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inherited disorders of homocysteine metabolism of the conceptus itself contribute to 
its death. 
From the results of our prospective study, we have concluded that periconceptional 
B-vitamin use may improve the subsequent pregnancy outcome in women with 
recurrent miscarriage and hyperhomocysteinemia (Chapter 9). To properly assess 
the efficacy of B-vitamin use in women with recurrent miscarriage, however, a 
randomized controlled trial would be needed. In the Netherlands, this option cannot 
be fulfilled because Dutch women planning to conceive are currently advised to use 
folic acid periconceptionally, 0.5 mg per day, in order to prevent the occurrence of 
NTD [Voedingsraad/Gezondheidsraad, 1993]. As a consequence, future prospective 
studies will be limited to a merely observational design. 
RECOMMENDATIONS FOR CLINICAL MANAGEMENT 
The routine screening procedure in couples with recurrent miscarriage should be 
limited to the identification of factors that (are likely to) predict subsequent pregnancy 
outcome (Chapter 2). Unfortunately, we could not assess whether untreated hyper-
homocysteinemia predicts pregnancy failure in the next pregnancy (Chapter 9). The 
results may indicate, however, that the oral methionine loading test as a tool for 
assessing a subject's homocysteine status should be part of the screening procedure 
in women with recurrent miscarriage. Table 12.1 presents a list of (possibly) predic-
tive factors that may be identified by history-taking, blood sampling or additional 
investigation procedures (Chapter 2). Future studies are needed to reconfirm the 
significance of known factors in predicting a successful pregnancy outcome, and to 
identify new prognostic variables. 
Therapeutic intervention should be based on proven favorable effects, established 
from well-conducted randomized controlled trials. However, no treatment modality 
currently available has been convincingly demonstrated to improve a couple's 
prognosis after experiencing consecutive miscarriages (Chapter 2). We have 
presented uncontrolled prospective data that indicate that periconceptional B-vitamin 
treatment of hyperhomocysteinemic women with recurrent miscarriage may be an ef-
fective means to improve their subsequent pregnancy outcome, especially in women 
without a previous successful pregnancy (Chapter 9). Unfortunately, randomized con-
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Table 12.1. Factors that possibly predict subsequent pregnancy outcome in couples with recurrent 
miscarriage, as identified by different steps of the screening procedure 
History-taking Blood test Additional procedures 
Number of previous miscarriages Hypersecretion of LHf Septate or bicomuate uterus*§ 
Number of previous live births Anticardiohpin antibodies 
Maternal age Hyperandrogenism 
Menstrual cycle irregulanty Antithyroid antibodies 
High natural-killer cell activity 
Balanced translocations* 
Hyperhomocystememia*t 
* No controlled prospective data available, although indirect evidence suggests predictive significance, 
t Luteinizing hormone, t By oral methionine loading test, § By ultrasound and/or hysterosalpmgo-
graphy and/or hysteroscopy 
trolled data will not become available from the Netherlands (see above) Additional 
observational studies will be necessary to further quantify the beneficial effect of B-
vitamm use in women with recurrent miscarriage in relation to their homocysteine 
status So far, a caring and empathetic attitude toward the couple seems to be the 
primary "therapy" physicians have to offer 
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Summary 
Chapter 1 
The pathophysiology of recurrent miscarriage is still poorly understood. A recent 
preliminary study has suggested a relationship between recurrent spontaneous 
abortion and hyperhomocysteinemia, i.e. a derangement of methionine-homocys-
teine metabolism resulting in elevated blood concentrations of homocysteine. The 
present thesis was designed to explore this possible association. 
Chapter 2 
A critical overview on the etiology of recurrent miscarriage is given. It is suggested 
that the management of couples with recurrent miscarriage should be aimed at a) 
identifying those factors that predict subsequent pregnancy outcome {prognostic 
profile), and, if possible, b) improving chances of achieving a normal pregnancy 
(treatment). In this respect, possible predictive factors and treatment modalities are 
discussed. 
Chapter 3 
Biochemical, (patho)physiological and clinical aspects of hyperhomocysteinemia, with 
special attention to vascular disease and adverse pregnancy outcome, are reviewed. 
Chapter 4 
The objectives, design and laboratory methods of this thesis are presented. 
Chapter 5 
Objective. To compare the concentrations of plasma homocysteine in premenopausal 
and postmenopausal women with normal pregnancy outcome, and to examine a 
possible relationship between the homocysteine and estrogen status. 
Design. Forty-six premenopausal and 26 postmenopausal healthy women without a 
history of vascular disease or adverse pregnancy outcome were recruited by public 
advertisement. The homocysteine status was studied by a standardized oral methio-
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nine loading test, and the estrogen status was assessed by the measurement of 
serum 17ß-estradiol. 
Results. Median fasting and postmethionine plasma homocysteine concentrations 
were significantly higher in postmenopausal women as compared to premenopausal 
women. In premenopausal women, postmethionine plasma homocysteine was 
negatively and significantly correlated to serum 17ß-estradiol. 
Conclusions. Plasma homocysteine concentrations, both fasting and after methionine 
loading, are significantly higher in postmenopausal women than in premenopausal 
women. In premenopausal women, the higher concentrations of serum 17ß-estradiol 
may account in part for the lower concentrations of postmethionine plasma homocys-
teine. 
Chapter 6 
Objectives. To establish the prevalence of hyperhomocysteinemia in women with 
recurrent miscarriage, and to examine the association between the homocysteine 
and vitamin status in these women. 
Design. Forty-six women with normal pregnancy outcome (controls) and 180 women 
with recurrent miscarriage (study group) were selected. The homocysteine status 
was studied by a standardized oral methionine loading test. Hyperhomocysteinemia 
was defined as a fasting and/or postmethionine plasma homocysteine concentration 
above the estimated 97.5 percentile level of the controls. The vitamin status was 
investigated by the measurement of serum and red cell folate, serum vitamin B12, 
and whole blood pyridoxal-5'-phosphate (PLP, an active form of vitamin B6) in a 
fasting state. 
Results. Hyperhomocysteinemia was diagnosed in 4 controls (9%) and 39 women of 
the study group (22%, Ρ < 0.05). In women with recurrent miscarriage, plasma 
homocysteine concentrations were significantly and negatively correlated to blood 
concentrations of folate and vitamin B12, but not to PLP. 
Conclusions. Hyperhomocysteinemia is associated with recurrent miscarriage. In 
women with recurrent miscarriage, folate and vitamin B12 are important determinants 
of the homocysteine status. 
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Chapter 7 
Objective. To estimate the prevalence of reduced cystathionine ß-synthase (CBS) 
activity and thermolabile 5,10-methylenetetrahydrofolate reductase (MTHFR) in 
hyperhomocysteinemic women with recurrent miscarriage. 
Design. CBS activities were measured in cultured fibroblasts of 12 control subjects, 
13 obligate heterozygotes for CBS deficiency, i.e. parents or children of patients 
suffering from homocystinuria due to homozygosity for CBS deficiency, and 7 hyper-
homocysteinemic women with recurrent miscarriage. Specific and residual MTHFR 
activities were measured in isolated lymphocytes of 23 control subjects, and 17 
hyperhomocysteinemic women with recurrent miscarriage. Thermolabile MTHFR was 
defined as a residual activity after heat inactivation of less than the lowest control 
value. 
Results. CBS activity within the range of obligate heterozygotes and thermolabile 
MTHFR were observed in one out of seven three out of 17 hyperhomocysteinemic 
women with recurrent miscarriage. 
Conclusions. Reduced CBS activity and thermolabile MTHFR were observed in a 
minor fraction of hyperhomocysteinemic women with recurrent miscarriage. Molecu-
lar genetic studies may be more appropiate in exploring these enzymic defects as a 
potential cause for hyperhomocysteinemia. 
Chapter 8 
Objective. To evaluate the effects of pyridoxine and folic acid treatment on elevated 
plasma homocysteine concentrations in women with adverse pregnancy outcome. 
Design. Nineteen women with recurrent miscarriage and 18 women with a history of 
placental vascuiopathy, i.e. infarction or abruption of the placenta, were selected 
after hyperhomocysteinemia was diagnosed by oral methionine loading test. They 
were orally treated by either one of three vitamin regimens, i.e. pyridoxine, 250 mg 
daily, or folic acid, 1 or 5 mg daily. A repeat loading test was performed at least four 
weeks after the start of treatment, and plasma homocysteine concentrations were 
compared. 
Results. No significant change of the median fasting plasma homocysteine concen-
tration was observed during pyridoxine treatment. By contrast, a significant decrease 
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of the median fasting plasma homocysteine concentration was noticed during folic 
acid treatment. The median reduction of postmethionine plasma homocysteine 
concentrations observed during treatment with folic acid, 5 mg daily, was significantly 
larger as compared to folic acid, 1 mg daily, or pyridoxine. 
Conclusions. Folic acid seems more effective in reducing elevated plasma homocys-
teine concentrations in women with adverse pregnancy outcome than pyridoxine. A 
randomized controlled study would be more appropiate to assess the true homo-
cysteine-lowering effects of these vitamins. 
Chapter 9 
Objective. To evaluate prospectively the effect of periconceptional B-vitamin treat-
ment on the outcome of the next pregnancy in women with recurrent miscarriage. 
Design. The homocysteine status of women with recurrent miscarriage was evalua-
ted by oral methionine loading test, and data on the outcome of the next pregnancy 
were collected. Ninety-five women were retrospectively classified in three groups by 
their homocysteine status at study entry and their periconceptional B-vitamin use, 
and pregnancy outcomes were compared. 
Results. Group I consisted of 23 hyperhomocysteinemic women who were treated 
with B-vitamins, group II of 17 normohomocysteinemic women who had used B-
vitamins as well, and group III of 55 normohomocysteinemic women who had not 
used any vitamins. The rate of livebirths was significantly higher in group I (83%) as 
compared to group III (53%). In hyperhomocysteinemic women, the rate of livebirths 
was highest in women without a previous successful pregnancy (11 of 11; 100%). 
Conclusion. Periconceptional B-vitamin use may favor women with recurrent miscar-
riage and hyperhomocysteinemia, especially those women without a previous suc-
cessful pregnancy. 
Chapter 10 
Objective. To compare the homocysteine status of women with recurrent miscarriage 
before and after a subsequent pregnancy. 
Design. Seventeen women with recurrent miscarriage were examined by oral methio-
nine loading test before conception and after the completion of a subsequent preg-
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nancy. Hyperhomocysteinemia was initially present in nine women. Normal plasma 
homocysteine concentrations were found in the remaining eight subjects. Plasma 
homocysteine concentrations before and after pregnancy were compared. 
Results. Overall, in 14 out of 17 women plasma homocysteine concentrations were 
essentially the same before and after pregnancy. No significant changes were obser­
ved in the median concentrations of plasma homocysteine and blood vitamins as 
measured by the initial and repeat test. 
Conclusion. Plasma homocysteine levels before and after pregnancy are about iden­
tical in most women with recurrent miscarriage. 
Chapter 11 
Objective. To establish the prevalence of hyperhomocysteinemia in women with a 
history of placental vasculopathy, i.e. abruption or infarction of the placenta. 
Design. Forty-six women with normal pregnancy outcome (controls) and 84 women 
with placental vasculopathy (study group) were selected. The homocysteine status 
was studied by a standardized oral methionine loading test. Hyperhomocysteinemia 
was defined as a fasting and/or postmethionine plasma homocysteine concentration 
above the estimated 97.5 percentile level of the controls. The vitamin status was 
investigated by the measurement of serum and red cell folate, serum vitamin B12, 
and whole blood pyridoxal-5'-phosphate (PLP, an active form of vitamin B6) in a 
fasting state. 
Results. Hyperhomocysteinemia was diagnosed in 4 controls (9%) and 26 women of 
the study group (31 %, Ρ < 0.05). The median concentrations of the vitamins studied 
were significantly lower in women of the study group as compared to the controls, 
except for red cell folate, where the median concentration was comparable in both 
groups. The median concentration of fasting plasma homocysteine, unlike post­
methionine plasma homocysteine, was significantly higher in women who experien­
ced placental vasculopathy in their first pregnancy than in women who had the same 
event after one or more uncomplicated pregnancies. 
Conclusion. Hyperhomocysteinemia is associated with placental vasculopathy. 
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Chapter 12 
The possible causal relationship between hyperhomocysteinemia and recurrent 
miscarriage is discussed, and suggestions for future research in this area are given. 
Hyperhomocysteinemia as a marker for deranged homocysteine metabolism is 
critically considered. Molecular genetic studies are mentioned as promising research 
activities into the etiology of hyperhomocysteinemia and recurrent miscarriage. A list 
of factors that are likely to predict subsequent pregnancy outcome, including hyper-
homocysteinemia, is proposed as (part of) a screening procedure in women with 
recurrent miscarriage. It is stated that no treatment modality currently available has 
been convincingly demonstrated to improve a couple's prognosis after experiencing 
consecutive miscarriages. In this respect, periconceptional B-vitamin use seems 
favorable in hyperhomocysteinemic women with recurrent miscarriage, but its bene-
ficial effect needs further quantification from future observational studies. 
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Samenvatting voor niet-vakgenoten 
Dit proefschrift, getiteld "Habituele abortus en hyperhomocysteïnaemie", beschrijft de 
resultaten van klinisch onderzoek naar de mogelijke rol van het stofwisselingsproduct 
homocysteine bij vrouwen met meerdere miskramen. In hoofdstuk 1 worden kort de 
globale doelstellingen van dit onderzoek uiteengezet. 
Habituele abortus wordt in dit proefschrift gedefinieerd als tenminste twee opeen-
volgende miskramen bij dezelfde partner, al of niet na de geboorte van een gezond 
kind. Men schat dat ongeveer 0,5 tot 1% van de vrouwen met zwangerschapswens 
met dit probleem te maken krijgt. Over het ontstaan van habituele abortus is weinig 
bekend. Vele factoren zijn beschreven als mogelijke oorzaak, doch meestal zonder 
overtuigend wetenschappelijk bewijs. In hoofdstuk 2 worden op grond van literatuur-
onderzoek een aantal factoren op een rijtje gezet. Er wordt gesteld dat de diagnos-
tiek en behandeling van paren met habituele abortus zou moeten berusten op twee 
pijlers, te weten a) inventarisatie van die factoren waarvan bekend is dat zij een 
voorspellende waarde hebben met betrekking tot een volgende zwangerschap 
(prognostisch profiel) en b) verbetering van de kansen op een normale zwanger-
schap met behulp van methoden waarvan het gunstige effect wetenschappelijk 
verantwoord is bewezen (therapie). In dit licht worden een aantal prognostische 
factoren en therapeutische alternatieven besproken. 
In hoofdstuk 3 worden de biochemische aspecten van hyperhomocysteïnaemie, een 
stoornis van de methionine-homocysteine stofwisseling, besproken. Tevens worden 
een aantal factoren die van invloed zijn op dit stofwisselingsproces nader toegelicht. 
Tot slot worden enkele klinische aspecten besproken. Een en ander wordt hieronder 
samengevat. 
Methionine is een belangrijk aminozuur dat voorkomt in vele voedingsproducten. Het 
dient als bouwsteen bij de aanmaak van nieuwe cellen, met name bij de vorming van 
erfelijk materiaal (DNA). Hierbij wordt als tussenproduct homocysteine gevormd. Bij 
de verdere verwerking van homocysteine worden twee routes gevolgd: enerzijds af-
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braak tot afvalstoffen die uit het lichaam verdwijnen (transsulfurering) en anderzijds 
hergebruik tot methionine (remethylering). Bij de transsulfurering speelt het enzym 
CS een belangrijke rol en wordt vitamine B6 verbruikt. Bij de remethylering zijn de 
enzymen MS en MTHFR van belang en worden de vitaminen B11 (foliumzuur) en 
B12 verbruikt. Genoemde enzymen en vitaminen dienen dus in voldoende hoeveel-
heid aanwezig te zijn teneinde het aanbod aan homocysteine te verwerken. Dit is 
belangrijk omdat men vermoedt dat homocysteine (in hoge concentraties) een 
schadelijke stof is. Hyperhomocysteïnaemie is een stoornis waarbij het homocysteï-
ne-gehalte in bloed te hoog is. Deze stoornis wordt als mogelijke oorzaak gezien van 
sommige hart- en vaatziekten, met name op jonge leeftijd. Bovendien zijn er aanwij-
zingen dat deze aandoening ook een rol speelt bij het ontstaan van afwijkingen aan 
de hersenen en het ruggemerg bij de ongeboren vrucht, zogenaamde neurale 
buisdefecten (NBD). Het is nog niet helemaal duidelijk hoe deze stofwisselingsziekte 
ontstaat. Theoretisch kunnen zowel enzym- als vitaminentekorten een rol spelen. 
Recentelijk onderzoek heeft aangetoond dat sommige vrouwen en hun NBD-kinde-
ren een bepaalde genetische afwijking hebben waardoor het eerder genoemde en-
zym MTHFR slecht functioneert. Bij deze vrouwen en kinderen blijken de homo-
cysteïne-concentraties in het bloed hoger te zijn dan bij degenen zonder die geneti-
sche afwijking. Sommige onderzoekers denken dat niet zozeer een verhoogd homo-
cysteïne-gehalte, maar een verlaagd methionine-gehalte van belang is. Immers, bij 
verminderde activiteit van MTHFR wordt minder homocysteine hergebruikt tot me-
thionine, waardoor de beschikbaarheid van laatstgenoemde stof mogelijk afneemt. 
In hoofdstuk 4 wordt uitgelegd welke vraagstellingen in dit proefschrift zijn onder-
zocht. Er wordt uiteengezet welke in- en uitsluitcriteria zijn gebruikt bij de werving van 
vrouwen met habituele abortus (onderzoeksgroep) en vrouwen met ongestoorde 
zwangerschappen (controle-groep). Daarnaast wordt beschreven welke onderzoeks-
en laboratoriummethoden zijn toegepast. Met name wordt ingegaan op de me-
thionine-belastingtest, een onderzoek waarbij het homocysteïne-gehalte in bloed vlak 
vóór en zes uur na de inname van methionine-poeder wordt gemeten. Tevens wor-
den bij dit onderzoek de bloedconcentraties van vitamine B6, foliumzuur en vitamine 
B12 bepaald. De test wordt gebruikt om hyperhomocysteïnaemie vast te stellen. 
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In hoofdstuk 5 tot en met 11 worden de resultaten van de verschillende onderzoeken 
beschreven. Deze worden hieronder samengevat. 
De homocysteïne-concentraties van vrouwen zijn hoger indien de overgang gepas-
seerd is. Dit heeft mogelijk te maken met een verminderde productie van hormonen 
(oestrogenen) bij vrouwen na de overgang (hoofdstuk 5). 
Vrouwen met habituele abortus hebben vaker hyperhomocysteïnaemie dan vrouwen 
met ongestoorde zwangerschappen (22% versus 9%). De homocysteïne-concentra-
ties zijn omgekeerd evenredig met de concentraties van foliumzuur en vitamine B12 
(hoofdstuk 6). 
Een verminderde aktiviteit van de enzymen CS en MTHFR komt slechts voor bij een 
kleine minderheid van de vrouwen met habituele abortus en hyperhomocysteïnae-
mie. Waarschijnlijk is het toekomstig onderzoek naar genetische afwijkingen een 
betere manier om enzymstoornissen op te sporen dan het direct meten van enzym-
aktiviteiten, zoals bij dit onderzoek werd gedaan (hoofdstuk 7). 
Het gebruik van vitamine B6- en/of foliumzuur-tabletten door vrouwen met habituele 
abortus en hyperhomocysteïnaemie gaat gepaard met een daling van het homo-
cysteïne-gehalte. Foliumzuur is hierbij beter werkzaam dan vitamine B6. Het is niet 
duidelijk of deze daling louter te danken valt aan de werkzaamheid van de onder-
zochte vitaminen of deels te wijten is aan een placebo-effect, dat wil zeggen een ver-
mindering van de homocysteïne-concentratie ten gevolge van andere, grotendeels 
onbekende factoren (hoofdstuk 8). 
Vrouwen met habituele abortus en hyperhomocysteïnaemie hebben bijna 65% kans 
om een gezond kind te krijgen indien zij vóór en tijdens de eerste weken van de 
zwangerschap B-vitaminen (vitamine B6, foliumzuur en/of vitamine B12) gebruiken. 
Dit is ongeveer evenveel als de gemiddelde kans op een ongestoorde zwangerschap 
bij alle vrouwen met zwangerschapswens. Met name vrouwen die voorheen uitslui-
tend miskramen hebben doorgemaakt, lijken het meest te profiteren van deze behan-
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deling (hoofdstuk 9). 
De homocysteïne-gehaltes bij vrouwen met habituele abortus, gemeten vóór en na 
een volgende zwangerschap, zijn vrijwel gelijk. Tijdens vitaminengebruik en zwanger-
schap treedt een daling op van deze concentraties. Deze waarneming bevestigt de 
veronderstelling dat de homocysteïne-stofwisseling voornamelijk gereguleerd wordt 
door genetisch bepaalde factoren (hoofdstuk 10). 
Hyperhomocysteïnaemie wordt vaker gevonden bij vrouwen met doorbloedingsstoor-
nissen van de moederkoek (placenta) dan bij vrouwen zonder deze afwijking (31 
versus 9%). Deze bevinding, in samenhang met die beschreven in hoofdstuk 6, laat 
zien dat specifieke vaatafwijkingen, zoals welke gevonden zijn bij weefselonderzoek 
van spontane miskramen en placenta-stoornissen in de late zwangerschap, mogelijk 
berusten op een gemeenschappelijke oorzaak, te weten hyperhomocysteïnaemie 
(hoofdstuk 11). 
In hoofdstuk 12 worden de gevonden resultaten besproken en met elkaar in verband 
gebracht. Op grond van de bevindingen wordt gesteld dat er een belangrijk verband 
bestaat tussen hyperhomocysteïnaemie en habituele abortus. De manier waarop ver-
hoogde homocysteïne-concentraties mogelijk habituele abortus veroorzaken is ech-
ter nog niet bekend. Verder onderzoek zal moeten uitwijzen of de beschadigende 
werking van homocysteine voornamelijk op de jonge vrucht of op de bloedvaten in de 
placenta plaatsvindt. Het is bovendien ook mogelijk dat een tekort aan B-vitaminen 
of methionine een rol speelt bij het ontstaan van miskramen. 
Op grond van het literatuuronderzoek dat wordt beschreven in hoofdstuk 2 en de 
resultaten van het verrichte onderzoek wordt een aanbeveling gedaan voor de scree-
ning en behandeling van paren met habituele abortus. De methionine-belastingtest 
lijkt een zinvol onderdeel van het screeningsonderzoek bij deze problematiek. Behan-
deling met B-vitaminen bij vrouwen met habituele abortus en hyperhomocysteïnae-
mie heeft mogelijk een gunstige invloed op de volgende zwangerschap. Verder 
onderzoek zal het nut van deze behandeling moeten onderbouwen. 
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Nawoord 
De totstandkoming van dit proefschrift heb ik mede aan de deskundigheid en hulp­
vaardigheid van vele mensen te danken. Hiervoor wil ik allen bijzonder bedanken. 
Een aantal van hen wil ik speciaal noemen: 
Prof. Dr. Т.К.A.B. Eskes, hoogleraar obstetrie & gynaecologie (promotor); 
Dr. H.J. Blom, biochemicus (co-promotor); 
Dr. G.H.J. Boers, internist-endocrinoloog (co-promotor); 
Dr. C.J.C.M. Hamilton, vrouwenarts (co-promotor); 
Dr. C.M.G. Thomas, biochemicus (co-promotor); 
Prof. Dr. J.M.F. Trijbels, hoogleraar klinische biochemie; 
Dr. L.A. Schellekens, vrouwenarts; 
Dr. M.J. van der Mooren, arts-onderzoeker; 
Drs. T.A.W. Goddijn-Wessel, arts-onderzoeker; 
Dr. G.F. Borm, statisticus; 
P.J. Hamel-van Bruggen, research-verpleegkundige; 
H. Crone, H.J.M. Fliervoet, G.L.M. Gommans, Y.S. Lawson en G.W.M. Theunissen, 
secretaressen; 
A. De Graaf-Hess, A. Janssen, H. van Lith-Zanders, D. van Oppenraaij-Emmerzaal, 
E. Stevens en M.T.W.B. Te Poele-Pothoff, medewerkers Laboratorium Kinderge­
neeskunde en Neurologie; 
Ing. M.F.G. Segers en J. Beunk, J. Droste, J. van Egmond, L. Geelen, M. Leupers en 
J. van de Ven, medewerkers Laboratorium Endocrinologie en Voortplanting; 
M.Th.E.C.Moorrees en M.B.J. Polman, medisch studenten. 
Tot slot betuig ik mijn dank aan alle vrouwen die bereid waren om aan het onderzoek 
mee te werken. Tevens dank ik alle gynaecologen, vroedvrouwen en huisartsen die 
hun patiënten hebben verwezen voor deelname aan het onderzoek. 
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Stellingen 
behorende bij het proefschrift 
Recurrent miscarriage and hyperhomocysteinemia 
ι 
De diagnostiek en behandeling van paren met habituele abortus zou moeten berus­
ten op twee pijlers, te weten a) het inventariseren van die factoren waarvan bekend is 
dat ZIJ een voorspellende waarde hebben met betrekking tot een volgende zwanger­
schap (prognostisch profiel) en b) het verbeteren van de kansen op een ongestoorde 
zwangerschap, uitsluitend met behulp van methoden waarvan het gunstige effect 
wetenschappelijk verantwoord is bewezen (therapie). 
Dit proefschrift 
II 
Hyperhomocysteïnaemie is een risicofactor voor habituele abortus, waarvan het oor-
zakelijke mechanisme vooralsnog onduidelijk is. 
Dit proefschrift 
III 
De orale methionine-belastmgtest lijkt een zinvol instrument in de diagnostiek van 
vrouwen met habituele abortus. 
Dit proefschrift 
IV 
Vrouwen met habituele abortus en hyperhomocysteïnaemie, die vóór en tijdens de 
eerste weken van de eerstvolgende zwangerschap B-vitaminen gebruiken, hebben 
mogelijk evenveel kans op de geboorte van een gezond kind als elke vrouw die 
zwanger wordt, ongeacht haar verloskundig verleden 
Dit proefschrift 
V 
Het advies aan a/te vrouwen in Nederland met zwangerschapswens om periconcep-
tioneel extra foliumzuur te gebruiken*) is om meerdere redenen verdedigbaar, doch 
is tot op heden wetenschappelijk onvoldoende onderbouwd 
'¡Gezondheidsraad/Voedingsraad Vervolgadvies inzake tohumzuurvoorziening in relatie tot neuraal-
buisdefecten Den Haag Voorlichtingsbureau voor de voeding, 1993 
VI 
De klassieke definitie van habituele abortus, waarbij wordt uitgegaan van tenminste 
dne opeenvolgende miskramen, dient te worden gewijzigd in een formulering waarbij 
het aantal miskramen in successie tenminste twee bedraagt. 
VII 
Medisch-wetenschappelijk onderzoek door artsen verdient het niet om gereduceerd 
te worden tot een noodzakelijke nevenactiviteit in de vrije uren. 
Vili 
Gezien de strikte internationale voorwaarden die men stelt aan (co-)auteurschap**) 
kan het aantal auteurs bij medisch-wetenschappelijke publicaties meestal beperkt 
worden tot drie. 
"international Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted 
to biomedical journals. JAMA 1993;269:22B2-6 
IX 
Ter bevordering van een objectieve beoordeling van wetenschappelijke manuscripten 
behoort in principe de identiteit van auteurs bij referenten onbekend te zijn. 
Maurice G.A.J. Wouters 
Nijmegen, 14 maart 1996 


